

ALDER BIOPHARMACEUTICALS INC  
Form DEF 14A  
April 30, 2018  
Table of Contents

**SCHEDULE 14A INFORMATION**

**Proxy Statement Pursuant to Section 14(a) of the  
Securities Exchange Act of 1934  
(Amendment No. )**

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

**Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to § 240.14a-12

**Alder BioPharmaceuticals, Inc.**

**(Name of Registrant as Specified In Its Charter)**

**(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)**

Payment of Filing Fee (Check the appropriate box)

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

**1.** Title of each class of securities to which transaction applies:

2. Aggregate number of securities to which transaction applies:
  
  
  
  
  
  
  
  
  
  
3. Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
  
  
  
  
  
  
  
  
  
  
4. Proposed maximum aggregate value of transaction:
  
  
  
  
  
  
  
  
  
  
5. Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

6. Amount Previously Paid:
  
  
  
  
  
  
  
  
  
  
7. Form, Schedule or Registration Statement No.:
  
  
  
  
  
  
  
  
  
  
8. Filing Party:
  
  
  
  
  
  
  
  
  
  
9. Date Filed:



Table of Contents

**ALDER BIOPHARMACEUTICALS, INC.**

**11804 North Creek Parkway South**

**Bothell, WA 98011**

**NOTICE OF ANNUAL MEETING OF STOCKHOLDERS**

**To Be Held On May 23, 2018**

Dear Alder Stockholder:

You are cordially invited to attend the Annual Meeting of Stockholders of Alder BioPharmaceuticals, Inc., a Delaware corporation (the *Company* ). The meeting will be held on Wednesday, May 23, 2018 at 10:00 a.m. local time at the offices of Cooley LLP, 1700 Seventh Avenue, Suite 1900, Seattle, Washington 98101-1355 for the following purposes:

1. To elect the three nominees for director named herein to the Board of Directors to hold office until the 2021 Annual Meeting of Stockholders.
2. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement accompanying this notice.
3. To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018.
4. To conduct any other business properly brought before the meeting.

These items of business are more fully described in the proxy statement accompanying this notice.

The record date for the Annual Meeting is April 20, 2018. Only stockholders of record at the close of business on that date may vote at the meeting or any adjournment thereof.

**Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting to Be Held on May 23, 2018 at the offices of**

**Cooley LLP, 1700 Seventh Avenue, Suite 1900, Seattle, Washington 98101-1355.**

The proxy statement and annual report to stockholders

are available at [www.proxyvote.com](http://www.proxyvote.com).

By Order of the Board of Directors  
Mark Litton  
Chief Business Officer, Treasurer and Corporate Secretary  
Bothell, WA

April 30, 2018

**You are cordially invited to attend the meeting in person. Whether or not you expect to attend the meeting, please complete, date, sign and return the enclosed proxy, or vote over the telephone or the internet as promptly as possible in order to ensure your representation at the meeting. A return envelope (which is postage prepaid if mailed in the United States) has been provided for your convenience. Voting instructions are printed on your proxy card and included in the accompanying proxy statement. Even if you have voted by proxy, you may still vote in person if you attend the meeting. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the meeting, you must obtain a proxy issued in your name from that record holder.**

Table of Contents

**TABLE OF CONTENTS**

	<b>Page</b>
<u>PROXY STATEMENT</u>	1
<u>QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING</u>	1
<u>PROPOSAL NO. 1 ELECTION OF DIRECTORS</u>	6
<u>PROPOSAL NO. 2 ADVISORY VOTE ON EXECUTIVE COMPENSATION</u>	11
<u>PROPOSAL NO. 3 RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</u>	12
<u>INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE</u>	14
<u>INFORMATION REGARDING COMMITTEES OF THE BOARD OF DIRECTORS</u>	15
<u>REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS</u>	21
<u>DIRECTOR COMPENSATION</u>	22
<u>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</u>	24
<u>SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE</u>	27
<u>EXECUTIVE OFFICERS</u>	28
<u>EXECUTIVE COMPENSATION</u>	31
<u>EQUITY COMPENSATION PLAN INFORMATION</u>	51
<u>TRANSACTIONS WITH RELATED PERSONS</u>	52
<u>HOUSEHOLDING OF PROXY MATERIALS</u>	54
<u>OTHER MATTERS</u>	55

**Table of Contents**

**ALDER BIOPHARMACEUTICALS, INC.**

**11804 North Creek Parkway South**

**Bothell, WA 98011**

**PROXY STATEMENT**

**FOR THE 2018 ANNUAL MEETING OF STOCKHOLDERS**

**May 23, 2018**

**QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING**

**Why am I receiving these materials?**

We have sent you these proxy materials because the Board of Directors of Alder BioPharmaceuticals, Inc. (the *Company*, *Alder*, we, us or our ) is soliciting your proxy to vote at the 2018 Annual Meeting of Stockholders (the *Annual Meeting* ), including at any adjournments or postponements of the meeting. You are invited to attend the annual meeting to vote on the proposals described in this proxy statement. However, you do not need to attend the meeting to vote your shares. Instead, you may simply complete, sign and return the enclosed proxy card, or follow the instructions below to submit your proxy over the telephone or through the internet.

We intend to mail these proxy materials on or about May 2, 2018 to all stockholders of record entitled to vote at the annual meeting.

**How do I attend the Annual Meeting?**

The meeting will be held on Wednesday, May 23, 2018 at 10:00 a.m. local time at the offices of Cooley LLP, 1700 Seventh Avenue, Suite 1900, Seattle, Washington 98101-1355. For directions, please call Cooley LLP at (206) 452-8700. Information on how to vote in person at the meeting is discussed below.

**Who can vote at the Annual Meeting?**

Only stockholders of record at the close of business on April 20, 2018 will be entitled to vote at the Annual Meeting. On this record date, there were 67,849,839 shares of common stock outstanding and entitled to vote.

*Stockholder of Record: Shares Registered in Your Name*

If on April 20, 2018, your shares were registered directly in your name with our transfer agent, American Stock Transfer & Trust Company, LLC, then you are a stockholder of record. As a stockholder of record, you may vote in person at the meeting or vote by proxy over the telephone, through the internet or by using a proxy card that you may request or that we may elect to deliver at a later time. Whether or not you plan to attend the meeting, we urge you fill out and return the enclosed proxy card or vote by proxy over the telephone or on the internet as instructed below to ensure your vote is counted.

*Beneficial Owner: Shares Registered in the Name of a Broker or Bank*

If on April 20, 2018, your shares were held, not in your name, but rather in an account at a brokerage firm, bank, dealer or other similar organization, then you are the beneficial owner of shares held in street name and these proxy materials are being forwarded to you by that organization. The organization holding your account is considered to be the stockholder of record for purposes of voting at the Annual Meeting. As a beneficial owner, you have the right to direct your broker or other agent regarding how to vote the shares in your account. You are also invited to attend the Annual Meeting. However, since you are not the stockholder of record, you may not vote your shares in person at the meeting unless you request and obtain a valid proxy from your broker or other agent.



## **Table of Contents**

### **What am I voting on?**

There are three matters scheduled for a vote:

election of three directors;

advisory approval of the compensation of our named executive officers, as disclosed in this proxy statement;  
and

ratification of selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018.

### **What if another matter is properly brought before the meeting?**

The Board of Directors knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the meeting, it is the intention of the persons named in the accompanying proxy to vote on those matters in accordance with their best judgment.

### **How do I vote?**

You may either vote **For** all the nominees to the Board of Directors or you may **Withhold** your vote for any nominee you specify. For your advisory vote on the compensation of our named executive officers and the ratification of the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm, you may vote **For** or **Against** or abstain from voting.

The procedures for voting are as follows:

#### *Stockholder of Record: Shares Registered in Your Name*

If you are a stockholder of record, you may vote in person at the Annual Meeting, vote by proxy using the enclosed proxy card, or vote by proxy over the telephone or through the internet. Whether or not you plan to attend the meeting, we urge you to vote by proxy to ensure your vote is counted. You may still attend the Annual Meeting and vote in person even if you have already voted by proxy.

To vote in person, come to the Annual Meeting and we will give you a ballot when you arrive.

To vote using the proxy card, simply complete, sign and date the enclosed proxy card and return it promptly in the envelope provided. If you return your signed proxy card to us before the Annual Meeting, we will vote your shares as you direct.

Edgar Filing: ALDER BIOPHARMACEUTICALS INC - Form DEF 14A

To vote over the telephone, dial toll-free 1-800-690-6903 using a touch-tone phone and follow the recorded instructions. You will be asked to provide the company number and control number from the enclosed proxy card. Your telephone vote must be received by 11:59 p.m., Eastern Time on May 22, 2018 to be counted.

To vote through the internet, go to <http://www.proxyvote.com> to complete an electronic proxy card. You will be asked to provide the company number and control number from the enclosed proxy card. Your internet vote must be received by 11:59 p.m., Eastern Time on May 22, 2018 to be counted.

*Beneficial Owner: Shares Registered in the Name of Broker or Bank*

If you are a beneficial owner of shares registered in the name of your broker, bank or other agent, you should have received a voting instruction form with these proxy materials from that organization rather than from us. Simply complete and mail the voting instructions form to ensure that your vote is counted. Alternatively, you may vote by telephone or over the internet as instructed by your broker or bank. To vote in person at the Annual Meeting, you must obtain a valid proxy from your broker, bank or other agent. Follow the instructions from your broker or bank included with these proxy materials, or contact your broker or bank to request a proxy form.

## **Table of Contents**

**Internet proxy voting will be provided to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and telephone companies.**

### **How many votes do I have?**

On each matter to be voted upon, you have one vote for each share of common stock you own as of April 20, 2018.

### **What happens if I do not vote?**

#### *Stockholder of Record: Shares Registered in Your Name*

If you are a stockholder of record and do not vote by completing your proxy card, by telephone, through the internet or in person at the Annual Meeting, your shares will not be voted.

#### *Beneficial Owner: Shares Registered in the Name of Broker or Bank*

If you are a beneficial owner and do not instruct your broker, bank, or other agent how to vote your shares, the question of whether your broker or nominee will still be able to vote your shares depends on whether the particular proposal is deemed to be a routine matter. Brokers and nominees can use their discretion to vote uninstructed shares with respect to matters that are considered to be routine, but not with respect to non-routine matters. Under the rules and interpretations of various national and regional securities exchanges, non-routine matters are matters that may substantially affect the rights or privileges of stockholders, such as mergers, stockholder proposals, elections of directors (even if not contested), executive compensation (including any advisory stockholder votes on executive compensation), and certain corporate governance proposals, even if management-supported. Ratification of the selection of auditors is considered a routine matter. Accordingly, your broker or nominee may not vote your shares on Proposal Nos. 1 and 2 without your instructions, but may vote your shares on Proposal No. 3, even in the absence of your instruction.

### **What if I return a proxy card or otherwise vote but do not make specific choices?**

If you return a signed and dated proxy card or otherwise vote without marking voting selections, your shares will be voted, as applicable, For the election of each nominee for director, For the advisory approval of named executive officer compensation, and For the ratification of the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018. If any other matter is properly presented at the meeting, your proxyholder (one of the individuals named on your proxy card) will vote your shares using his best judgment.

### **Who is paying for this proxy solicitation?**

We will pay for the entire cost of soliciting proxies. In addition to these proxy materials, our directors and employees may also solicit proxies in person, by telephone, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies. We may also reimburse brokerage firms, banks and other agents for the cost of forwarding proxy materials to beneficial owners. We may retain a proxy solicitation firm to assist in the solicitation of proxies and related advice and informational support, and in that event, we will pay such firm customary fees.



**Table of Contents**

**What does it mean if I receive more than one set of proxy materials?**

If you receive more than one set of proxy materials, your shares may be registered in more than one name or in different accounts. Please follow the voting instructions on the proxy cards in the proxy materials to ensure that all of your shares are voted.

**Can I change my vote after submitting my proxy?**

*Stockholder of Record: Shares Registered in Your Name*

Yes. You can revoke your proxy at any time before the final vote at the meeting. If you are the record holder of your shares, you may revoke your proxy in any one of the following ways:

You may submit another properly completed proxy card with a later date.

You may grant a subsequent proxy by telephone or through the internet.

You may send a timely written notice that you are revoking your proxy to our Corporate Secretary at 11804 North Creek Parkway South, Bothell, WA 98011.

You may attend the Annual Meeting and vote in person. Simply attending the meeting will not, by itself, revoke your proxy.

Your most current proxy card or telephone or internet proxy is the one that is counted.

*Beneficial Owner: Shares Registered in the Name of Broker or Bank*

If your shares are held by your broker or bank as a nominee or agent, you should follow the instructions provided by your broker or bank.

**When are stockholder proposals and director nominations due for next year's annual meeting?**

To be considered for inclusion in next year's proxy materials, your proposal must be submitted in writing by January 2, 2019, to our Corporate Secretary at 11804 North Creek Parkway South, Bothell, WA 98011, and must comply with all applicable requirements of Rule 14a-8 promulgated under the Securities Exchange Act of 1934, as amended (the *Exchange Act*); *provided, however*, that if our 2019 Annual Meeting of Stockholders is held before April 23, 2019 or after June 22, 2019, then the deadline is a reasonable amount of time prior to the date we begin to print and mail our proxy statement for the 2019 Annual Meeting of Stockholders. If you wish to submit a proposal (including a director nomination) at the 2019 Annual Meeting of Stockholders that is not to be included in next year's proxy materials, the proposal must be received by our Corporate Secretary not later than the close of business on February 22, 2019 nor earlier than the close of business on January 23, 2019; *provided, however*, that if our 2019 Annual Meeting of Stockholders is held before April 23, 2019 or after June 22, 2019, then the proposal must be received not earlier than the close of business on the 120th day prior to such meeting and not later than the close of business on the later of the 90th day prior to such meeting or the 10th day following the day on which public announcement of the date of such

meeting is first made. You are also advised to review our bylaws, which contain additional requirements about advance notice of stockholder proposals and director nominations.

**How are votes counted?**

Votes will be counted by the inspector of election appointed for the meeting, who will separately count, for the proposal to elect directors, votes For, Withhold and broker non-votes; with respect to the advisory approval of the executive compensation of our named executive officers, votes For, Against, and broker non-votes; and, with respect to the proposal to ratify the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm, votes For, Against and abstentions.

**Table of Contents****What are broker non-votes ?**

As discussed above, when a beneficial owner of shares held in street name does not give instructions to the broker or nominee holding the shares as to how to vote on matters deemed to be non-routine, the broker or nominee cannot vote the shares. These unvoted shares are counted as broker non-votes.

**How many votes are needed to approve each proposal?**

The following table summarizes the minimum votes needed to approve each proposal and the effect of abstentions and broker non-votes.

<b>Proposal Number</b>	<b>Proposal Description</b>	<b>Vote Required for Approval</b>	<b>Effect of Abstentions or Withheld Votes</b>	<b>Effect of Broker Non-Votes</b>
1	Election of Directors	The three nominees receiving the most For votes will be elected	None	None
2	Advisory approval of the compensation of named executive officers	For votes from the holders of a majority of shares present in person or represented by proxy and entitled to vote on the matter	Against	None
3	Ratification of the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2018	For votes from the holders of a majority of shares present in person or represented by proxy and entitled to vote on the matter	Against	None

**What is the quorum requirement?**

A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if stockholders holding at least a majority of the outstanding shares entitled to vote are present at the meeting in person or represented by proxy. On the record date, there were 67,849,839 shares outstanding and entitled to vote. Thus, the holders of 33,924,920 shares must be present in person or represented by proxy at the Annual Meeting to have a quorum.

Your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank or other nominee) or if you vote in person at the meeting. Abstentions and broker non-votes will be counted towards the quorum requirement. If there is no quorum, the holders of a majority of shares present at the meeting in person or represented by proxy may adjourn the Annual Meeting to another date.

**How can I find out the results of the voting at the Annual Meeting?**

Preliminary voting results will be announced at the Annual Meeting. In addition, final voting results will be published in a current report on Form 8-K that we expect to file within four business days after the Annual Meeting. If final

voting results are not available to us in time to file a Form 8-K within four business days after the meeting, we intend to file a Form 8-K to publish preliminary results and, within four business days after the final results are known to us, file an amended Form 8-K to publish the final results.

**What proxy materials are available on the internet?**

The proxy statement and 2017 Annual Report are available at [www.proxyvote.com](http://www.proxyvote.com).



**Table of Contents****PROPOSAL NO. 1****ELECTION OF DIRECTORS**

Our Board of Directors is divided into three classes. Each class consists, as nearly as possible, of one-third of the total number of directors, and each class has a three-year term. Vacancies on the Board of Directors may be filled only by persons elected by a majority of the remaining directors. A director elected by the Board of Directors to fill a vacancy in a class, including vacancies created by an increase in the number of directors, shall serve for the remainder of the full term of that class and until the director's successor is duly elected and qualified.

The Board of Directors presently has nine members. There are three Class I directors whose term of office expires in 2018. If elected at the Annual Meeting, each of the nominees would serve until the 2021 annual meeting and until his successor has been duly elected and qualified, or, if sooner, until the director's death, resignation or removal. It is the Company's policy to invite directors and nominees for director to attend the Annual Meeting. Three of our directors attended the 2017 Annual Meeting of Stockholders.

The following table sets forth information with respect to the three nominees for election at the Annual Meeting and the directors whose terms of office will continue after the Annual Meeting, as of March 31, 2018:

<b>Director</b>			
<b>Name</b>	<b>Age</b>	<b>Since</b>	<b>Position</b>
<i>Class I Directors Nominees for Election at the Annual Meeting</i>			
Paul B. Cleveland	61	August 2015	Interim President and Chief Executive Officer and Director
Stephen M. Dow	62	April 2005	Chairman of the Board of Directors
A. Bruce Montgomery	64	October 2010	Director
<i>Class II Directors Continuing in Office until the 2019 Annual Meeting</i>			
Paul Carter	57	September 2015	Director
Deepika R. Pakianathan	53	December 2007	Director
Wendy L. Yarno	63	March 2017	Director
<i>Class III Directors Continuing in Office until the 2020 Annual Meeting</i>			
Jeremy Green	44	April 2018	Director
Heather Preston	52	December 2007	Director
Clay B. Siegall	57	November 2005	Director

Each of the nominees was recommended for election by the Nominating and Corporate Governance Committee of the Board of Directors. Each of the nominees is currently a director of the Company. Mr. Dow and Dr. Montgomery were previously elected by the stockholders as Class I Directors. Mr. Cleveland was appointed to the Board of Directors by the then-current members of the Board of Directors to fill a vacant seat.

Directors are elected by a plurality of the votes of the holders of shares of common stock present in person or represented by proxy and entitled to vote on the election of directors. Accordingly, the three nominees receiving the highest number of affirmative votes will be elected. Shares represented by executed proxies will be voted, if authority to do so is not withheld, for the election of the three nominees. If any nominee becomes unavailable for election as a result of an unexpected occurrence, shares that would have been voted for that nominee will instead will be voted for

the election of a substitute nominee proposed by Alder. Each person nominated for election has agreed to serve if elected. The Company's management has no reason to believe that any nominee will be unable to serve.

**NOMINEES FOR ELECTION FOR A THREE-YEAR TERM EXPIRING AT THE 2021 ANNUAL MEETING**

*Paul B. Cleveland.* Mr. Cleveland has served as our Interim President and Chief Executive Officer since March 2018 and has served as a member of our Board of Directors since August 2015. Since June 2017, Mr. Cleveland

---

**Table of Contents**

has served as the Chairman of the board of directors of Adverum Biotechnologies, Inc., a biotechnology company. Mr. Cleveland previously served as the Executive Chairman of Adverum from October 2016 to June 2017, and as President and Chief Executive Officer from December 2015 to October 2016. From May 2015 to November 2015, Mr. Cleveland served as President and Chief Executive Officer at Celladon Corporation, a clinical-stage biotechnology company, and previously served as Celladon's President and Chief Financial Officer since June 2014. From February 2013 to August 2013, Mr. Cleveland served as Executive Vice President, Corporate Strategy and Chief Financial Officer of Aragon Pharmaceuticals, Inc., a biotechnology company. From April 2011 to February 2013, Mr. Cleveland served as General Partner and Chief Operating Officer of Mohr Davidow Ventures, a venture capital firm. From January 2006 to February 2011, Mr. Cleveland served as Executive Vice President, Corporate Development and Chief Financial Officer of Affymax, Inc., a biopharmaceutical company. From April 2004 to December 2005, he served as a managing director at Integrated Finance, Ltd., an investment bank. From September 1996 to April 2003, Mr. Cleveland served as a managing director at investment bank J.P. Morgan Chase and Co. and a predecessor firm, Hambrecht & Quist. From January 1993 to September 1996, Mr. Cleveland was a partner at Cooley LLP, from December 1988 to December 1992, he was a corporate attorney at Sidley Austin LLP and from September 1981 to November 1988, he was a corporate attorney at Davis Polk & Wardwell LLP. Mr. Cleveland currently serves as the Chairman of the board of directors of Adverum Biotechnologies. Mr. Cleveland previously served on the board of directors of Sangamo BioSciences, Inc. from November 2008 to August 2016, and on the board of directors of Celladon from May 2015 to November 2015. Mr. Cleveland received an A.B. from Washington University in St. Louis and a J.D. from Northwestern University School of Law.

The Nominating and Corporate Governance Committee believes that Mr. Cleveland is qualified to serve on our Board of Directors due to his experience as the President and Chief Executive Officer, Chief Financial Officer, a member of the board of directors, and audit committee chair of several biotechnology companies, which provides additional insight to our Board of Directors on the operational, financial and best practices of such companies.

*Stephen M. Dow.* Mr. Dow has served as a member of our Board of Directors since April 2005 and as our chairperson since September 2005. Mr. Dow has served as a General Partner with Sevin Rosen Funds, a venture capital firm, since 1983. During his time with Sevin Rosen Funds, Mr. Dow has served as a director on numerous boards of directors, both public and private. Mr. Dow previously served on the board of directors of Citrix Systems Inc. from 1989 to 2015 and Cytokinetics, Inc. from 1998 to 2013. Mr. Dow holds an M.B.A. and a B.A. in Economics from Stanford University.

The Nominating and Corporate Governance Committee believes that Mr. Dow is qualified to serve on our Board of Directors due to his diversity of experience in the development, financing and management of emerging technology and life sciences companies.

*A. Bruce Montgomery, M.D.* Dr. Montgomery has served as a member of our Board of Directors since October 2010. Since March 2017, Dr. Montgomery has served as the Chief Executive Officer of Avalyn Pharma Inc., a pharmaceutical company. In 2010, Dr. Montgomery founded Cardeas Pharma Corporation, a biotechnology company, where he served as Chief Executive Officer and a member of the board of directors from 2010 to December 2016. In 2001, he founded Corus Pharma, Inc., a biotechnology company, and served as its Chief Executive Officer from 2001 through its acquisition in 2006 by Gilead Sciences, Inc. He continued on at Gilead post-acquisition until 2010 and served as Senior Vice President and Head of Respiratory Therapeutics, where he successfully led the approval of Cayston (aztreonam) as a treatment for cystic fibrosis patients. From 1993 to 2000, Dr. Montgomery held positions within the research and development group of PathoGenesis Corporation, a biotechnology company. From 1989 to 1993, Dr. Montgomery worked at Genentech, Inc., a biotechnology company. Dr. Montgomery currently serves on the board of directors of CytoDyn Inc. and Xencor Inc. Dr. Montgomery holds an M.D. and a B.S. in Chemistry from the University of Washington.



**Table of Contents**

The Nominating and Corporate Governance Committee believes that Dr. Montgomery is qualified to serve on our Board of Directors due to his many years of research and development and executive management experience in the biotechnology industry, including overseeing the successful development of several approved products, including inhalable tobramycin and dornas alfa, or Pulmozyme.

**THE BOARD OF DIRECTORS RECOMMENDS**

**A VOTE IN FAVOR OF EACH NAMED NOMINEE.**

**Table of Contents****DIRECTORS CONTINUING IN OFFICE UNTIL THE 2019 ANNUAL MEETING**

*Paul R. Carter.* Mr. Carter has served as a member of our Board of Directors since September 2015. From April 2006 to August 2016, Mr. Carter served in various roles at Gilead Sciences, Inc., a research based biopharmaceutical company, most recently serving as Executive Vice President, Commercial Operations. Prior to joining Gilead, Mr. Carter spent 15 years in the pharmaceutical industry with GlaxoSmithKline and its legacy companies. During his time with GlaxoSmithKline, Mr. Carter gained increasing levels of senior experience as General Manager in Europe and later as a Regional Head of the International Business in Asia. Mr. Carter currently serves on the board of directors of Hutchison China Meditech Ltd, a biopharmaceutical company. Mr. Carter holds a degree in Business Studies from the Ealing School of Business and Management (now merged into University of West London) and is a Fellow of the United Kingdom's Chartered Institute of Management Accountants.

The Nominating and Corporate Governance Committee believes that Mr. Carter is qualified to serve on our Board of Directors due to his experience in the pharmaceutical industry, including his key involvement with the launches of several important medicines.

*Deepika R. Pakianathan, Ph.D.* Dr. Pakianathan has served as a member of our board of directors since April 2013. Since 2001, Dr. Pakianathan has been a Managing Member at Delphi Ventures, a venture capital firm focused on biotechnology and medical device investments, and leads the firm's biotechnology investment activities. From 1998 to 2001, Dr. Pakianathan was a senior biotechnology banker at JPMorgan, a global investment bank, from 1997 to 1998, she was a Research analyst covering biotech at Genesis Merchant Group and from 1993 to 1997 she was a post-doctoral research scientist at Genentech. Dr. Pakianathan serves on the boards of directors of Karyopharm Therapeutics, Inc., a public biopharmaceutical company, where she serves as a member of its audit and compensation committees, OncoMed Pharmaceuticals, Inc., a public biopharmaceutical company, where she serves as a member of its audit and compensation committees and Calithera Biosciences, Inc., a biopharmaceutical company, where she serves as the lead independent director and is a member of its compensation committee and chair of its nominating and governance committee. From 2004 to 2016, Dr. Pakianathan served on the board of directors of Alexza Pharmaceuticals, Inc., from 2009 to February 2013, Dr. Pakianathan served on the board of directors of PTC Therapeutics, Inc., and from 2007 to 2012, Dr. Pakianathan served on the board of directors of Relypsa, Inc., each a public biopharmaceutical company. Dr. Pakianathan received a B.Sc. from the University of Bombay, India, a M.Sc. from The Cancer Research Institute at the University of Bombay, India, and an M.S. and Ph.D. from Wake Forest University.

The Nominating and Corporate Governance Committee believes that Dr. Pakianathan is qualified to serve on our Board of Directors due to her experience as a venture capital investor in, and director of, multiple biotechnology companies, as well as her experience as a biotechnology investment banker, research analyst and research scientist.

*Wendy L. Yarno.* Ms. Yarno has served as a member of our Board of Directors since March 2017. Ms. Yarno retired in September 2008 from Merck & Co., Inc. following a 26-year career there in commercial and human resource positions of increasing seniority, most recently Chief Marketing Officer before she retired. Prior to this role, she served as General Manager, Cardiovascular/Metabolic United States Business Unit, where she had P&L responsibility for Merck's largest therapeutic area, and as Senior Vice President, Human Resources. From September 2010 through September 2011, Ms. Yarno was the Chief Marketing Officer of HemoShear LLC, a biotechnology research company and leading developer of human cell-based surrogate systems for discovery and assessment of new drug compounds. Ms. Yarno currently serves on the board of directors of the biopharmaceuticals companies Global Blood Therapeutics, Inc., Inovio Pharmaceuticals, Inc. and MyoKardia, Inc., and on the board of directors and as chairperson of Aratana Therapeutics, Inc., a pet therapeutics company. Ms. Yarno previously served as member of the board of directors of St. Jude Medical, Inc., a medical device company, from April 2002 until January 2017 when St. Jude Medical was

acquired by Abbott Laboratories, Medivation, Inc., a biopharmaceutical company, from April 2013 until September 2016 when Medivation was acquired by Pfizer Inc., and Durata Therapeutics, Inc., a pharmaceutical company, from August 2014 until November 2014 when Durata was acquired

**Table of Contents**

by Actavis plc. Ms. Yarno holds a B.S. in Business Administration from Portland State University and an M.B.A. from Temple University.

The Nominating and Corporate Governance Committee believes that Ms. Yarno is qualified to serve on our Board of Directors due to her extensive experience in the pharmaceutical industry, in particular her role at Merck in which she led a global organization charged with all aspects of supporting pre- and post-launch commercialization of pharmaceuticals in more than 20 therapeutics areas.

**DIRECTORS CONTINUING IN OFFICE UNTIL THE 2020 ANNUAL MEETING**

*Jeremy Green.* Mr. Green has served as a member of our Board of Directors since April 2018. Since 2007, Mr. Green has served as the Founder and Portfolio Manager of Redmile Group, LLC, a San Francisco-based investment firm that focuses on the healthcare sector. Prior to founding Redmile Group, LLC, Mr. Green served as Co-Founder and Director of Research at Steeple Capital L.P., and as an analyst at Andor Capital Management, L.L.C. Prior to that, Mr. Green served as a Managing Director at Citigroup Inc. and Head of the European Healthcare Research Team covering medical technology, biotech and healthcare services. Mr. Green holds a B.A. in Natural Science Biological Sciences and an M.A. from the University of Oxford.

The Nominating and Corporate Governance Committee believes that Mr. Green is qualified to serve on our Board of Directors due to his experience as an investor in the healthcare sector, as well as his experience as a biotechnology research analyst.

*Heather Preston, M.D.* Dr. Preston has served as a member of our Board of Directors since December 2007. Since 2005, Dr. Preston has served as a Partner and Managing Director at TPG BioTech, a biotechnology venture capital firm. Prior to joining TPG BioTech, Dr. Preston served for two years as a medical device and biotechnology venture capital investor at JP Morgan Partners, LLC, a private equity firm. Prior to that, she was an Entrepreneur-in-Residence at New Enterprise Associates, a venture capital firm. From 1997 to 2002, Dr. Preston served as a leader of the pharmaceutical and medical products consulting practice at McKinsey & Co. in New York. Dr. Preston currently serves on the board of directors of Otonomy, Inc. and on numerous private company boards of directors. Dr. Preston holds an M.D. from the University of Oxford and a B.S. in Biochemistry from the University of London.

The Nominating and Corporate Governance Committee believes that Dr. Preston is qualified to serve on our Board of Directors due to her substantial experience as an investor in biopharmaceutical and life sciences companies, as well as her experience at McKinsey & Co. advising large pharmaceutical companies.

*Clay B. Siegall, Ph.D.* Dr. Siegall has served as a member of our Board of Directors since November 2005. In 1998, Dr. Siegall co-founded Seattle Genetics, Inc., a biotechnology company, and currently serves as its President, Chief Executive Officer and Chairman of the Board of Directors. From 1991 to 1997, Dr. Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute, National Institutes of Health from 1988 to 1991. In addition to Seattle Genetics and Alder, Dr. Siegall currently serves on the board of directors of Ultragenyx Pharmaceutical Inc. and he previously served on the board of directors of Mirna Therapeutics, Inc. from January 2013 to December 2016. Dr. Siegall holds a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland.

The Nominating and Corporate Governance Committee believes that Dr. Siegall is qualified to serve on our Board of Directors due to his experience in founding and building Seattle Genetics, his significant executive leadership experience and his role overseeing the successful development of an approved product.





**Table of Contents**

**PROPOSAL NO. 2**

**ADVISORY VOTE ON EXECUTIVE COMPENSATION**

Under the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, and Section 14A of the Exchange Act, the Company's stockholders are entitled to vote to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in this proxy statement in accordance with Securities and Exchange Commission (the *SEC*) rules.

At the 2016 Annual Meeting, we asked our stockholders to indicate if we should hold a say-on-pay vote every year, every two years or every three years. Consistent with the recommendation of our Board of Directors, our stockholders indicated by advisory vote their preference to hold a say-on-pay vote annually. After consideration of the voting results, and based upon its prior recommendation, our Board of Directors elected to hold a stockholder say-on-pay vote annually.

This vote is not intended to address any specific item of compensation, but rather the overall compensation of the Company's named executive officers and the policies and practices described in this proxy statement. The compensation of the Company's named executive officers subject to the vote is disclosed in the compensation tables and the related narrative disclosure contained in this proxy statement. The Company believes that its compensation policies and decisions are consistent with current market practices. Compensation of the Company's named executive officers is designed to enable the Company to attract and retain talented and experienced executives to lead the Company successfully in a competitive environment.

Accordingly, the Board of Directors is asking the stockholders to indicate their support for the compensation of the Company's named executive officers as described in this proxy statement by casting a non-binding advisory vote **FOR** the following resolution:

**RESOLVED**, that the compensation paid to the Company's named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the compensation tables and narrative discussion is hereby **APPROVED**.

Because the vote is advisory, it is not binding on the Board of Directors or the Company. Nevertheless, the views expressed by the stockholders, whether through this vote or otherwise, are important to management and the Board of Directors and, accordingly, the Board of Directors and the Compensation Committee intend to consider the results of this vote in making determinations in the future regarding executive compensation arrangements.

Unless our Board of Directors modifies its policy on the frequency of future advisory votes on the compensation of our named executive officers, the next advisory vote on the compensation of our named executive officers will be held at the 2019 Annual Meeting of Stockholders. In addition, our stockholders will be able to indicate by advisory vote at our 2022 annual meeting their preference as to the frequency of future advisory votes.

Advisory approval of this proposal requires the vote of the holders of a majority of the shares present in person or represented by proxy.

**THE BOARD OF DIRECTORS RECOMMENDS**

**A VOTE IN FAVOR OF PROPOSAL NO. 2.**



**Table of Contents****PROPOSAL NO. 3****RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

The Audit Committee of the Board of Directors has selected PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018, and has further directed that management submit the selection of its independent registered public accounting firm for ratification by the stockholders at the Annual Meeting. PricewaterhouseCoopers LLP has audited the Company's financial statements since 2007. Representatives of PricewaterhouseCoopers LLP are expected to be present at the Annual Meeting. They will have an opportunity to make a statement if they so desire and will be available to respond to appropriate questions.

Neither the Company's Bylaws nor other governing documents or law require stockholder ratification of the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm. However, the Audit Committee of the Board of Directors is submitting the selection of PricewaterhouseCoopers LLP to the stockholders for ratification as a matter of good corporate practice. If the stockholders fail to ratify the selection, the Audit Committee of the Board of Directors will reconsider whether or not to retain that firm. Even if the selection is ratified, the Audit Committee of the Board of Directors in its discretion may direct the appointment of different independent auditors at any time during the year if they determine that such a change would be in the best interests of the Company and its stockholders.

The affirmative vote of the holders of a majority of the shares present in person or represented by proxy and entitled to vote on the matter at the Annual Meeting will be required to ratify the selection of PricewaterhouseCoopers LLP.

**PRINCIPAL ACCOUNTANT FEES AND SERVICES**

The following table represents aggregate fees billed to the Company for the years ended December 31, 2017 and 2016, by PricewaterhouseCoopers LLP, the Company's principal accountant.

	<b>2017</b>	<b>2016</b>
	<b>(in thousands)</b>	
Audit Fees <sup>(1)</sup>	\$ 734	\$ 612
Audit-related Fees		
Tax Fees		
All Other Fees <sup>(2)</sup>	1	
<b>Total Fees</b>	<b>\$ 735</b>	<b>\$ 612</b>

(1) Includes the aggregate fees related to the audits of our annual consolidated financial statements and the reviews of our interim financial statements, services rendered in connection with the filing of our registration statements, and the issuance of comfort letters and consents.

(2) Includes fees related to a subscription service for PricewaterhouseCoopers LLP's accounting guidance and automated disclosure checklist.

All fees described above were pre-approved by the Audit Committee.

**PRE-APPROVAL POLICIES AND PROCEDURES**

The Charter of the Audit Committee provides for the pre-approval of audit and non-audit services rendered by the Company's independent registered public accounting firm, PricewaterhouseCoopers LLP. The Audit Committee generally pre-approves specified services in the defined categories of audit services, audit-related services and tax services up to specified amounts. Pre-approval may also be given as part of the Audit

**Table of Contents**

Committee's approval of the scope of the engagement of the independent auditor or on an individual, explicit, case-by-case basis before the independent auditor is engaged to provide each service. The pre-approval of services may be delegated to one or more of the Audit Committee's members, but the decision must be reported to the full Audit Committee at its next scheduled meeting.

The Audit Committee has determined that the rendering of services other than audit services by PricewaterhouseCoopers LLP is compatible with maintaining the principal accountant's independence.

**THE BOARD OF DIRECTORS RECOMMENDS**

**A VOTE IN FAVOR OF PROPOSAL NO. 3.**

---

**Table of Contents**

**INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE**

**INDEPENDENCE OF THE BOARD OF DIRECTORS**

As required under The Nasdaq Stock Market LLC ( *Nasdaq* ) listing standards, a majority of the members of a listed company's board of directors must qualify as independent, as affirmatively determined by the board of directors. Our Board of Directors consults with the Company's counsel to ensure that the Board of Directors' determinations are consistent with relevant securities and other laws and regulations regarding the definition of independent, including those set forth in pertinent listing standards of Nasdaq, as in effect from time to time.

Consistent with these considerations, after review of all relevant identified transactions or relationships between each director, or any of his or her family members, and the Company, its senior management and its independent auditors, the Board of Directors has affirmatively determined that the following eight directors are independent directors within the meaning of the applicable Nasdaq listing standards: Mr. Dow, Mr. Carter, Mr. Green, Dr. Montgomery, Dr. Pakianathan, Dr. Preston, Dr. Siegall and Ms. Yarno. In making this determination, the Board of Directors found that none of these directors had a material or other disqualifying relationship with Alder. The Board of Directors also considered Mr. Green's role as the Founder and Portfolio Manager of Redmile Group, LLC, and our relationship with Redmile Group, LLC and affiliated entities as significant stockholders in making the determination that Mr. Green is independent. Mr. Cleveland, our Interim President and Chief Executive Officer, is not an independent director by virtue of his current employment with Alder.

**BOARD LEADERSHIP STRUCTURE**

The Board of Directors of the Company has an independent chair, Mr. Dow, who has authority, among other things, to call and preside over Board of Directors meetings, including meetings of the independent directors, and to set meeting agendas. Accordingly, the Chairman of the Board has substantial ability to shape the work of the Board of Directors. The Company believes that separation of the positions of Chairman of the Board and Chief Executive Officer reinforces the independence of the Board of Directors in its oversight of the business and affairs of the Company. In addition, the Company believes that having an independent Chairman of the Board creates an environment that is more conducive to objective evaluation and oversight of management's performance, increasing management accountability and improving the ability of the Board to monitor whether management's actions are in the best interests of the Company and its stockholders. As a result, the Company believes that having an independent Chairman of the Board can enhance the effectiveness of the Board of Directors as a whole.

**ROLE OF THE BOARD OF DIRECTORS IN RISK OVERSIGHT**

One of the Board of Directors' key functions is informed oversight of the Company's risk management process. The Board of Directors does not have a standing risk management committee, but rather administers this oversight function directly through the Board of Directors as a whole, as well as through various Board of Directors standing committees that address risks inherent in their respective areas of oversight. In particular, our Board of Directors is responsible for monitoring and assessing strategic risk exposure, including a determination of the nature and level of risk appropriate for the Company. Our Audit Committee has the responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The Audit Committee also monitors compliance with legal and regulatory requirements, in addition to oversight of the performance of our internal audit function. Our Nominating and Corporate Governance Committee monitors the effectiveness of our corporate governance guidelines, including whether they are successful in preventing illegal or improper liability-creating conduct. Our Compensation Committee assesses and monitors whether any of our

compensation policies and programs has the potential to encourage excessive risk-taking.



**Table of Contents****MEETINGS OF THE BOARD OF DIRECTORS**

The Board of Directors met seven times during 2017. All directors attended at least 75% of the aggregate number of meetings of the Board of Directors and of the committees on which they served, held during the portion of 2017 for which they were directors or committee members, respectively. The Board of Directors also acts by written consent from time to time.

**INFORMATION REGARDING COMMITTEES OF THE BOARD OF DIRECTORS**

The Board of Directors has several committees, including an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. The following table provides the current membership information for each such committee:

<b>Name</b>	<b>Audit</b>	<b>Compensation</b>	<b>Nominating and Corporate Governance</b>
Stephen M. Dow	X*		
Paul Carter	X	X	
Paul B. Cleveland			
Jeremy Green			X
A. Bruce Montgomery			X
Deepika R. Pakianathan		X	
Heather Preston	X		
Clay B. Siegall		X*	X
Wendy Yarno		X	X*

\* Committee Chairperson

Below is a description of such committees of the Board of Directors, including membership of such committees during 2017.

The Board of Directors has determined that each member of each committee meets the applicable Nasdaq rules and regulations regarding independence and each member is free of any relationship that would impair his or her individual exercise of independent judgment with regard to the Company.

**AUDIT COMMITTEE**

The Audit Committee of the Board of Directors was established by the Board of Directors in accordance with Section 3(a)(58)(A) of the Exchange Act, to oversee the Company's corporate accounting and financial reporting processes and audits of its financial statements. The primary functions of this committee include:

reviewing disclosures by a prospective registered public accounting firm of relationships between such firm or its members and us or our personnel in financial oversight roles to determine independence of a

prospective registered public accounting firm;

reviewing and pre-approving the engagement of our independent registered public accounting firm to perform audit services and any permissible non-audit services;

evaluating the performance and assessing qualifications of our independent registered public accounting firm and deciding whether to retain their services;

monitoring the rotation of partners of our independent registered public accounting firm on our audit engagement team as required by law;

**Table of Contents**

considering and adopting clear policies regarding pre-approval by our Audit Committee of our employment of individuals employed or formerly employed by our independent registered accounting firm and engaged on our account;

reviewing our annual and quarterly financial statements and reports and discussing the statements and reports with our independent registered public accounting firm and management;

preparing the Audit Committee report required by the SEC to be included in our annual proxy statement;

reviewing, with our independent registered public accounting firm and management, significant issues that may arise regarding accounting principles and financial statement presentation, as well as matters concerning the scope, adequacy and effectiveness of our financial controls;

reviewing and discussing with management and our independent registered accounting firm, our guidelines and policies with respect to risk assessment and risk management, any management or internal control letters, and any conflicts or disagreements regarding financial reporting, accounting practices of policies or other matters significant to our financial statements or the report of our independent registered accounting firm;

considering and reviewing with our management, our independent registered accounting firm, and outside counsel or advisors, correspondence with regulatory or governmental agencies and any published reports that may raise material issues regarding our financial statements or accounting policies;

conducting an annual assessment of the performance of the Audit Committee and its members, and the adequacy of its charter;

establishing procedures for the receipt, retention and treatment of complaints received by us regarding financial controls, accounting or auditing matters; and

reporting to our Board of Directors material issues in connection with our Audit Committee's responsibilities. During 2017, the Audit Committee was composed of three directors: Mr. Cleveland (chairman), Mr. Dow and Dr. Preston. Mr. Carter replaced Mr. Cleveland as a member and Mr. Dow replaced Mr. Cleveland as chairman of the Audit Committee following Mr. Cleveland's appointment as Interim President and Chief Executive Officer.

The Audit Committee met four times during 2017. The Board of Directors has adopted a written Audit Committee charter that is available to stockholders on the Company's website at <http://investor.alderbio.com/corporate-governance>.

The Board of Directors reviews the Nasdaq listing standards definition of independence for Audit Committee members on an annual basis and has determined that all members of the Company's Audit Committee are independent

(as independence is currently defined in Rule 5605(c)(2)(A)(i) of the Nasdaq listing standards and Rule 10A-3 of the Exchange Act). Our Board of Directors also determined that each member of the Audit Committee can read and understand fundamental financial statements in accordance with applicable requirements.

The Board of Directors has also determined that Mr. Dow qualifies as an audit committee financial expert, as defined in applicable SEC rules. The Board of Directors made a qualitative assessment Mr. Dow's level of knowledge and experience based on a number of factors, including formal education and experience.

**Table of Contents**

**Compensation Committee**

The Compensation Committee of the Board of Directors acts on behalf of the Board of Directors to review, adopt and oversee the Company's compensation strategy, policies, plans and programs, including:

recommending to our Board of Directors for determination and approval the compensation and other terms of employment of our chief executive officer and his performance in light of relevant corporate performance goals and objectives;

reviewing and approving the compensation and other terms of employment of our executive officers (other than our chief executive officer) and other employees, and corporate performance goals and objectives relevant to such compensation, and assessing the attainment of the prior year's corporate goals and objectives;

appointing, compensating, and overseeing the work of compensation consultants, independent legal counsel or any other advisors engaged for the purpose of advising the committee after assessing the independence of such person in accordance with applicable Nasdaq rules;

reviewing and recommending to our Board of Directors the compensation of our directors;

reviewing and recommending to our Board of Directors and administering the equity incentive plans, compensation plans, and similar programs advisable for us, as well as evaluating and approving modification or termination of existing plans and programs;

establishing policies with respect to equity compensation arrangements;

recommending to our Board of Directors compensation-related proposals to be considered at our annual meeting of stockholders;

preparing the Compensation Committee report required by the SEC to be included in our annual proxy statement;

reviewing and discussing with management any conflicts of interest raised by the work of a compensation consultant or advisor retained by our Compensation Committee or management and how such conflict is being addressed, and preparing any necessary disclosure in our annual proxy statement in accordance with applicable SEC rules; and

reviewing and evaluating, at least annually, the performance of the Compensation Committee and the adequacy of its charter.

In addition, the Compensation Committee reviews with management the Company's Compensation Discussion and Analysis and considers whether to recommend that it be included in proxy statements and other filings.

During 2017, the Compensation Committee was composed of four directors: Mr. Carter, Dr. Pakianathan, Dr. Siegall (chairman) and Ms. Yarno. Ms. Yarno was appointed as a member of the Compensation Committee in September 2017. All members of the Company's Compensation Committee are independent (as independence is currently defined in Rule 5605(d)(2) of the NASDAQ listing standards), are non-employee directors as defined in Rule 16b-3 promulgated under the Exchange Act and are outside directors as that term is defined in Section 162(m) of the Internal Revenue Code of 1986, as amended, or Section 162(m). During 2017, the Compensation Committee met three times and acted by written consent. The Board of Directors has adopted a written Compensation Committee charter that is available to stockholders on the Company's website at <http://investor.alderbio.com/corporate-governance>.

#### *Compensation Committee Processes and Procedures*

Typically, the Compensation Committee meets semiannually and with greater frequency if necessary, and acts by written consent from time to time, as appropriate. The agenda for each meeting is usually developed by the Chair of the Compensation Committee, in consultation with management. The Compensation Committee meets

---

**Table of Contents**

regularly in executive session. However, from time to time, various members of management and other employees as well as outside advisors or consultants may be invited by the Compensation Committee to make presentations, to provide financial or other background information or advice or to otherwise participate in Compensation Committee meetings. The Chief Executive Officer may not participate in, or be present during, any deliberations or determinations of the Compensation Committee regarding his compensation or individual performance objectives. The charter of the Compensation Committee grants the Compensation Committee full access to all books, records, facilities and personnel of the Company. In addition, under the charter, the Compensation Committee has the authority to obtain, at the expense of the Company, advice and assistance from compensation consultants and internal and external legal, accounting or other advisors and other external resources that the Compensation Committee considers necessary or appropriate in the performance of its duties. The Compensation Committee has direct responsibility for the oversight of the work of any consultants or advisers engaged for the purpose of advising the Committee. In particular, the Compensation Committee has the sole authority to retain, in its sole discretion, compensation consultants to assist in its evaluation of executive and director compensation, including the authority to approve the consultant's reasonable fees and other retention terms. Under the charter, the Compensation Committee may select, or receive advice from, a compensation consultant, legal counsel or other adviser to the Compensation Committee, other than in-house legal counsel and certain other types of advisers, only after taking into consideration six factors, prescribed by the SEC and Nasdaq, that bear upon the adviser's independence; however, there is no requirement that any adviser be independent.

Under its charter, the Compensation Committee may form, and delegate authority to, subcommittees as appropriate. In 2014, the Compensation Committee formed a Non-Officer Stock Award Committee, currently composed of both (i) the Company's Chief Executive Officer and (ii) either the Company's Chief Business Officer or the Company's Head of Human Resources, to which it delegated authority to grant, without any further action required by the Compensation Committee, equity-based compensation awards to employees who are not officers of the Company. The purpose of this delegation of authority is to enhance the flexibility of equity award administration within the Company and to facilitate the timely grant of equity awards to non-management employees, particularly new employees, within specified limits approved by the Compensation Committee. In particular, the Non-Officer Stock Award Committee may not (1) grant awards covering more than an aggregate of 250,000 shares of common stock per fiscal quarter, (2) grant awards covering more shares than have been approved by the Company's stockholders under the 2014 Equity Incentive Plan, (3) grant awards to the Company's Section 16 reporting officers or to persons who are then serving on the Non-Officer Stock Award Committee, (4) grant an award covering more than 30,000 shares of common stock to any individual employee in any fiscal quarter, and (5) grant awards unless they are granted in accordance with the approved guidelines established by the Board of Directors of Compensation Committee; provided, however, that the Non-Officer Stock Award Committee can exceed such guideline by up to 20% in the discretion of the Non-Officer Stock Award Committee, if such increase is necessary as a result of a competitive or strategic hiring condition; provided, further, that the Compensation Committee may delegate additional authority to the Non-Officer Stock Award Committee from time-to-time in excess of the award limit per fiscal quarter in (1) above.

We adopted a non-employee director compensation policy in March 2014 and adopted an Executive Severance Benefit Plan in May 2014. The Executive Severance Benefit Plan was amended and restated in December 2016. Our non-employee director compensation policy is described under "Director Compensation" below and our Executive Severance Benefit Plan is described under "Executive Compensation Compensation Discussion and Analysis Post-Termination Protection" below.

**Nominating and Corporate Governance Committee**

The Nominating and Corporate Governance Committee of the Board of Directors oversees our corporate governance function. The primary functions of this committee include:

reviewing periodically and evaluating director performance of our Board of Directors and its applicable committees, and recommending to our Board of Directors and management areas for improvement;



**Table of Contents**

interviewing, evaluating, nominating and recommending individuals for membership on our Board of Directors;

overseeing and reviewing our processes and procedures to provide information to our Board of Directors and its committees;

reviewing and recommending to our Board of Directors any amendments to our corporate governance policies; and

reviewing and assessing, at least annually, the performance of the Nominating and Corporate Governance Committee and the adequacy of its charter.

During 2017, the Nominating and Corporate Governance Committee was composed of four directors: Mr. Dow (chairman), Mr. Cleveland, Dr. Montgomery and Dr. Preston. Ms. Yarno replaced Mr. Dow as chairperson and Dr. Siegall replaced Dr. Preston and Mr. Cleveland as members of the Nominating and Corporate Governance Committee in 2018. Mr. Green was appointed as a member of the Nominating and Corporate Governance Committee in April 2018. All members of the Nominating and Corporate Governance Committee are independent (as independence is currently defined in Rule 5605(a)(2) of the Nasdaq listing standards). During 2017, the Nominating and Corporate Governance Committee met four times and acted by written consent. The Board of Directors has adopted a written Nominating and Corporate Governance Committee charter that is available to stockholders on the Company's website at <http://investor.alderbio.com/corporate-governance>.

The Board of Directors believes that candidates for director should have certain minimum qualifications, including the ability to read and understand basic financial statements, being over 21 years of age and having the highest personal integrity and ethics. The Nominating and Corporate Governance Committee also considers such factors as possessing relevant expertise which qualifies him or her to offer advice and guidance to management, having sufficient time to devote to the affairs of the Company, demonstrated excellence in his or her field, having the ability to exercise sound business judgment and having the commitment to rigorously represent the long-term interests of the Company's stockholders. However, the Board of Directors retains the right to modify these qualifications from time to time. Candidates for director nominees are reviewed in the context of the current composition of the Board of Directors, the operating requirements of the Company and the long-term interests of stockholders. In conducting this assessment, the Nominating and Corporate Governance Committee typically considers diversity, age, skills and such other factors as it deems appropriate, given the current needs of the Board of Directors and the Company, to maintain a balance of knowledge, experience and capability.

In the case of incumbent directors whose terms of office are set to expire, the Nominating and Corporate Governance Committee reviews these directors' overall service to the Company during their terms, including the number of meetings attended, level of participation, quality of performance and any other relationships and transactions that might impair the directors' independence. In the case of new director candidates, the Nominating and Corporate Governance Committee also determines whether the nominee is independent for Nasdaq purposes, which determination is based upon applicable Nasdaq listing standards, applicable SEC rules and regulations and the advice of counsel, if necessary. The Nominating and Corporate Governance Committee then uses its network of contacts to compile a list of potential candidates, but may also engage, if it deems appropriate, a professional search firm. The Nominating and Corporate Governance Committee conducts any appropriate and necessary inquiries into the backgrounds and qualifications of possible candidates after considering the function and needs of the Board of Directors. The Nominating and Corporate Governance Committee meets to discuss and consider the candidates

qualifications and then selects a nominee for recommendation to the Board of Directors.

The Nominating and Corporate Governance Committee will consider director candidates recommended by stockholders. The Nominating and Corporate Governance Committee does not intend to alter the manner in which it evaluates candidates, including the minimum criteria set forth above, based on whether or not the candidate was recommended by a stockholder. Stockholders who wish to recommend individuals for consideration by the Nominating and Corporate Governance Committee to become nominees for election to the Board of Directors may do so by delivering a written recommendation to the Nominating and Corporate

## **Table of Contents**

Governance Committee at the following address: 11804 North Creek Parkway South, Bothell, WA 98011. Submissions must include the full name of the proposed nominee, a description of the proposed nominee's business experience for at least the previous five years, complete biographical information, a description of the proposed nominee's qualifications as a director and a representation that the nominating stockholder is a beneficial or record holder of the Company's stock. Any such submission must be accompanied by the written consent of the proposed nominee to be named as a nominee and to serve as a director if elected.

## **STOCKHOLDER COMMUNICATIONS WITH THE BOARD OF DIRECTORS**

Historically, the Company has not provided a formal process related to stockholder communications with the Board of Directors. Nevertheless, every effort has been made to ensure that the views of stockholders are heard by the Board of Directors or individual directors, as applicable, and that appropriate responses are provided to stockholders in a timely manner. The Company believes its responsiveness to stockholder communications to the Board of Directors has been excellent. Nevertheless, the Nominating and Corporate Governance Committee will consider from time to time the adoption of a formal process for stockholder communications with the Board of Directors and, if adopted, publish it promptly and post it to the Company's website.

## **CODE OF BUSINESS CONDUCT AND ETHICS**

We have adopted a Code of Business Conduct and Ethics that applies to all of our employees, officers and directors, including those officers responsible for financial reporting. The Code of Business Conduct and Ethics is available on the Company's website at <http://investor.alderbio.com/corporate-governance>. If the Company makes any substantive amendments to the Code of Business Conduct and Ethics or grants any waiver from a provision of the Code to any executive officer or director, the Company will promptly disclose the nature of the amendment or waiver on its website.

## **CORPORATE GOVERNANCE GUIDELINES**

In March 2014, the Board of Directors adopted Corporate Governance Guidelines to assure that the Board of Directors will have the necessary authority and practices in place to review and evaluate the Company's business operations as needed and to make decisions that are independent of the Company's management. The guidelines are also intended to align the interests of directors and management with those of the Company's stockholders. The Corporate Governance Guidelines set forth the practices the Board of Directors intends to follow with respect to board composition and selection, board meetings and involvement of senior management, Chief Executive Officer performance evaluation and succession planning, and board committees and compensation. The Corporate Governance Guidelines, as well as the charters for each committee of the Board of Directors, may be viewed at <http://investor.alderbio.com/corporate-governance>.

**Table of Contents**

**REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS<sup>(1)</sup>**

The Audit Committee has reviewed and discussed the audited financial statements for the fiscal year ended December 31, 2017 with management of the Company. The Audit Committee has discussed with the independent registered public accounting firm the matters required to be discussed by Auditing Standard No. 16, *Communications with Audit Committees*, as adopted by the Public Company Accounting Oversight Board ( **PCAOB** ). The Audit Committee has also received the written disclosures and the letter from the independent registered public accounting firm required by applicable requirements of the PCAOB regarding the independent accountants' communications with the Audit Committee concerning independence, and has discussed with the independent registered public accounting firm the accounting firm's independence. Based on the foregoing, the Audit Committee has recommended to the Board of Directors that the audited financial statements be included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017.

Mr. Paul B. Cleveland (Chair)

Mr. Stephen Dow

Dr. Heather Preston

- (1) The material in this report is not soliciting material, is not deemed filed with the SEC and is not to be incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended (the **Securities Act** ), or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.

**Table of Contents**

**DIRECTOR COMPENSATION**

We provide cash and equity compensation to our non-employee directors. Randall C. Schatzman, Ph.D, who served as our President and Chief Executive Officer for all of 2017, was an employee of Alder and was compensated for his service as an employee and did not receive any additional compensation for his service on our Board of Directors.

*Compensation Policy.* Our Board of Directors adopted our non-employee director compensation policy in March 2014 and amended the policy in September 2015. Pursuant to the policy, each non-employee director receives an annual base cash retainer of \$40,000 for such service, to be paid monthly. The non-executive chairperson of our Board of Directors receives an additional annual base cash retainer of \$20,000 for such service, to be paid monthly.

The policy also provides that we compensate the members of our Board of Directors for service on our committees as follows:

The chairperson of our Audit Committee receives an annual cash retainer of \$15,000 for such service, paid monthly, and each of the other members of the Audit Committee receives an annual cash retainer of \$7,500, paid monthly.

The chairperson of our Compensation Committee receives an annual cash retainer of \$10,000 for such service, paid monthly, and each of the other members of the Compensation Committee receives an annual cash retainer of \$5,000, paid monthly.

The chairperson of our Nominating and Corporate Governance Committee receives an annual cash retainer of \$7,000 for such service, paid monthly, and each of the other members of the Nominating and Corporate Governance Committee receives an annual cash retainer of \$3,500, paid monthly.

The policy further provides for the grant of equity awards as follows:

Upon a non-employee director's election to our Board of Directors, such director will receive an option to purchase 30,000 shares of our common stock. One-third of the shares subject to each stock option will vest on the one-year anniversary of the date of grant, one-third of the shares subject to each stock option will vest on the two-year anniversary of the date of grant and one-third of the shares subject to each stock option will vest on the three year anniversary of the date of grant, such that the option is fully vested on the third anniversary of the date of grant, subject to the director's continued service through each such vesting date and will vest in full upon a change in control.

On the date of each annual meeting of stockholders, each non-employee director will receive an option to purchase an additional 15,000 shares of our common stock. The shares subject to each option will vest on the date of the following annual stockholder meeting.

Each of these options will be granted with an exercise price equal to the fair market value of our common stock on the date of such grant.

*Processes and Procedures for Determining Director Compensation.* The charter of the Compensation Committee vests in the Compensation Committee the responsibility for reviewing director compensation and recommending changes to the Board. It is the practice of the Compensation Committee to seek input from executive officers and outside compensation consultants as it deems appropriate. The Compensation Committee reviews and assesses non-employee director pay levels from time to time with assistance from Compensia, an independent compensation consultant, which prepares a comprehensive assessment of our non-employee director compensation program. In September 2015, we reviewed non-employee director compensation of our peer companies against our compensation practices. As a result of that review, the Compensation Committee adjusted the initial and annual equity compensation of our non-employee directors.

**Table of Contents**

*Director Compensation Table.* The following table sets forth information regarding compensation earned by or paid to our non-employee directors during 2017.

<b>Name</b>	<b>Cash Compensation</b>	<b>Option Awards<sup>(1)</sup></b>	<b>Total</b>
Paul Carter	\$ 45,000	\$ 140,603	\$ 185,603
Paul B. Cleveland	58,660	140,603	199,263
Stephen M. Dow	74,500	140,603	215,103
Jeremy Green <sup>(2)</sup>			
A. Bruce Montgomery, M.D.	43,500	140,603	184,103
Deepika R. Pakianathan, Ph.D. <sup>(3)</sup>	45,000	140,603	185,603
Heather Preston, M.D.	51,000	140,603	191,603
Clay B. Siegall, Ph.D.	50,000	140,603	190,603
Wendy L. Yarno <sup>(4)</sup>	31,399	482,201	513,600

- (1) The amounts in this column reflect the aggregate grant date fair value of each option award granted during the year, computed in accordance with FASB ASC Topic 718. The valuation assumptions used in determining such amounts are described in Note 13 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017. The table below lists the aggregate number of shares subject to outstanding option awards held by each of our non-employee directors.

<b>Name</b>	<b>Number of Shares Subject to Outstanding Options as of December 31, 2017</b>
Paul Carter	60,000
Paul B. Cleveland	60,000
Stephen M. Dow	36,350
A. Bruce Montgomery, M.D.	68,166
Deepika R. Pakianathan, Ph.D.	36,350
Heather Preston, M.D.	36,350
Clay B. Siegall, Ph.D.	68,165
Wendy L. Yarno	45,000

- (2) Mr. Green was appointed to our Board of Directors in April 2018 and therefore did not earn or receive any compensation from us during 2017.
- (3) Cash compensation earned by Dr. Pakianathan during 2017 was paid to Delphi Management Partners VII, L.L.C.
- (4) Ms. Yarno was appointed to our Board of Directors in March 2017.

**Table of Contents**

**SECURITY OWNERSHIP OF  
CERTAIN BENEFICIAL OWNERS AND MANAGEMENT**

The following table sets forth certain information with respect to the beneficial ownership of our capital stock as of March 31, 2018, for:

each of our named executive officers;

each of our directors;

each of our co-founders;

all of our directors and executive officers as a group; and

each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock.

We have based our calculation of beneficial ownership on 67,848,701 shares of common stock outstanding on March 31, 2018. This table is based upon information supplied by officers, directors and principal stockholders and Schedules 13D and 13G filed with the SEC. Beneficial ownership is determined in accordance with the rules of the SEC and generally includes any shares over which a person exercises sole or shared voting or investment power. Shares of common stock issuable under options or warrants that are exercisable within 60 days after March 31, 2018 are deemed beneficially owned and such shares are used in computing the percentage ownership of the person holding the options or warrants, but are not deemed outstanding for the purpose of computing the percentage ownership of any other person. The information contained in the following table is not necessarily indicative of beneficial ownership for any other purpose, and the inclusion of any shares in the table does not constitute an admission of beneficial ownership of those shares.

Unless otherwise indicated below, to our knowledge, all persons named in the table have sole voting and dispositive power with respect to their shares of common stock, except to the extent authority is shared by spouses under community property laws. Unless otherwise indicated below, the address of each beneficial owner listed in the table below is c/o Alder BioPharmaceuticals, Inc. 11804 North Creek Parkway South, Bothell, WA 98011.

<b>Beneficial Owner</b>	<b>Beneficial Ownership</b>	
	<b>Number of Shares</b>	<b>Percent of Total</b>
<b>5% Stockholders:</b>		
Entities affiliated with Redmile Group, LLC <sup>(1)</sup>	6,808,306	9.99%
The Vanguard Group <sup>(2)</sup>	5,359,236	7.9
BlackRock, Inc. <sup>(3)</sup>	4,976,663	7.3



Wellington Management Group LLP <sup>(4)</sup>	4,515,093	6.7
Foresite Capital and its affiliates <sup>(5)</sup>	4,147,871	6.1
<b>Named Executive Officers, Directors and Co-Founders:</b>		
Randall C. Schatzman, Ph.D. <sup>(6)</sup>	1,062,787	1.5
Larry K. Benedict <sup>(7)</sup>	151,127	*
John A. Latham, Ph.D. <sup>(8)</sup>	571,540	*
Mark J. Litton, Ph.D. <sup>(9)</sup>	393,451	*
Elisabeth A. Sandoval, M.B.A. <sup>(10)</sup>	123,438	*
Jeffrey T.L. Smith <sup>(11)</sup>	333,484	*
Stephen M. Dow <sup>(12)</sup>	318,540	*
Paul Carter <sup>(13)</sup>	50,000	*
Paul B. Cleveland <sup>(4)</sup>	50,001	*
Jeremy Green <sup>(1)</sup>	6,808,306	9.99
A. Bruce Montgomery, M.D. <sup>(15)</sup>	77,794	*
Deepika R. Pakianathan, Ph.D. <sup>(16)</sup>	2,874,882	4.2
Heather Preston, M.D. <sup>(17)</sup>	36,350	*
Clay B. Siegall, Ph.D. <sup>(18)</sup>	99,879	*
Wendy L. Yarno <sup>(19)</sup>	30,833	*
All executive officers and directors as a group (18 persons) <sup>(20)</sup>	12,157,082	17.4

**Table of Contents**

- \* Represents beneficial ownership of less than one percent (1%) of the outstanding common stock.
- (1) Based in part on information provided in a Schedule 13D/A filed with the SEC by Redmile Group, LLC and Jeremy Green on April 26, 2018. According to such filing, Redmile Group, LLC has shared voting and dispositive power with respect to: (i) 1,062,676 shares of our common stock and 46,596 shares of our non-voting Class A-1 Convertible Preferred Stock ( Class A-1 Preferred Stock ) held by Redmile Capital Fund, LP, (ii) 262,671 shares of our common stock and 204,772 shares of Class A-1 Preferred Stock held by Redmile Capital Offshore Fund II, Ltd., (iii) 154,403 shares of our common stock and 7,594 shares of Class A-1 Preferred Stock held by Redmile Capital Offshore Fund (ERISA), Ltd., (iv) 2,129,754 shares of our common stock and 95,210 shares of Class A-1 Preferred Stock held by Redmile Capital Offshore Fund, Ltd., (v) 47,400 shares of our common stock and 112,847 shares of Class A-1 Preferred Stock held by Redmile Strategic Master Fund, LP, (vi) 2,143,630 shares of our common stock and 258,249 shares of Class A-1 Preferred Stock held by a separately managed account, (vii) 434,439 shares of our common stock held by Map 20 Segregated Portfolio, a segregated portfolio of LMA SPC, and (viii) 270,793 shares of our common stock held by P Redmile Ltd. Redmile Group, LLC is the investment manager/adviser to each of the private investment vehicles and separately managed accounts listed in items (i) through (viii) and, in such capacity, exercises sole voting and investment power over all of the shares held by such vehicles and accounts and may be deemed to be the beneficial owner of these shares. Jeremy Green serves as the managing member of Redmile Group, LLC and also may be deemed to be the beneficial owner of these shares. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. The Class A-1 Preferred Stock is initially convertible into shares of our common stock on a one-for-ten basis. Pursuant to the Certificate of Designation of Preferences, Rights and Limitations of Class A-1 Convertible Preferred Stock (the Certificate of Designation ), we may not effect any conversion of the Class A-1 Preferred Stock, and a holder of the Class A-1 Preferred Stock does not have the right to convert any portion of the Class A-1 Preferred Stock held by such holder, to the extent that, after giving effect to the conversion set forth in a notice of conversion, such conversion would result in such holder, together with such holder's affiliates, and any persons acting as a group together with such holder or affiliates, beneficially owning in excess of the Beneficial Ownership Limitation. The Beneficial Ownership Limitation is 9.99% of the shares of common stock then issued and outstanding, which percentage may be changed at a holder's election upon 61 days' notice to us. The 6,808,306 shares of our common stock beneficially owned by Redmile Group, LLC represents 9.99% of the outstanding shares of our common stock issued and outstanding as of March 31, 2018, including 302,540 shares of our common stock issuable upon conversion of 30,254 shares of Class A-1 Preferred Stock, which, due to the Beneficial Ownership Limitation, is the maximum number of shares of Class A-1 Preferred Stock that could be converted to shares of our common stock as of March 31, 2018. The address of Redmile Group, LLC is One Letterman Drive, Bldg D, Ste D3-300, San Francisco, CA 94129.
- (2) Based solely on information provided in a Schedule 13G/A filed with the SEC on behalf of The Vanguard Group on February 12, 2018 reflecting its common stock holdings as of December 31, 2017. According to this filing, The Vanguard Group has sole voting power with respect to 78,190 shares and sole dispositive power with respect to 5,280,990 shares of our common stock, and shared dispositive power with respect to 78,246 shares of our common stock. The address of The Vanguard Group is 100 Vanguard Blvd., Malvern, PA 19355.
- (3) Based solely on information provided in a Schedule 13G/A filed with the SEC on behalf of BlackRock, Inc. on January 29, 2018 reflecting its common stock holdings as of December 31, 2017. According to this filing, BlackRock, Inc. has sole voting power with respect to 4,866,162 shares and sole dispositive power with respect to 4,976,663 shares of our common stock. The address of BlackRock, Inc. is 55 East 52nd Street, New York, NY 10055.
- (4) Based on information contained in a Schedule 13G/A filed on February 8, 2018 reflecting its common stock holdings as of December 31, 2017. Wellington Management Group LLP, Wellington Group Holdings LLP,

Wellington Investment Advisors Holdings LLP and Wellington Management Company LLP (collectively, Wellington ) beneficially own 4,515,093 shares of our common stock which are owned of record by clients of one or more investment advisers directly or indirectly owned by Wellington Management Group LLP. The address of Wellington is 280 Congress Street, Boston, MA 02210.

**Table of Contents**

- (5) Based solely on information provided in a Schedule 13G/A filed by Foresite Capital Fund II, L.P. ( FCF II ), Foresite Capital Management II, LLC ( FCM II ), Foresite Capital Fund III, L.P. ( FCF III ), Foresite Capital Management III, LLC ( FCM III ) and James Tananbaum with the SEC on February 13, 2018, reflecting common stock holdings as of December 31, 2017 (including shares represented by call options exercisable within sixty days of December 31, 2017). FCM II is the general partner of FCF II. FCM III is the general partner of FCF III. Tananbaum is the managing member of each of FCM II, which is the general partner of FCF II, and FCM III, which is the general partner of FCF III. James Tananbaum may be deemed to have sole power to vote these shares. The address of these entities is c/o Foresite Capital Management, LLC, 101 California Street, Suite 4100, San Francisco, California 94111.
- (6) Represents (a) 116,347 shares held directly by Dr. Schatzman and (b) 946,440 shares issuable pursuant to stock options exercisable within 60 days of March 31, 2018.
- (7) Represents (a) 32,134 shares held directly by Mr. Benedict and (b) 118,993 shares issuable pursuant to stock options exercisable within 60 days of March 31, 2018.
- (8) Represents (a) 243,208 shares held directly by Dr. Latham and (b) 328,332 shares issuable pursuant to stock options exercisable within 60 days of March 31, 2018.
- (9) Represents (a) 101,342 shares held directly by Dr. Litton, (b) 78,000 shares held in trust for the benefit of Dr. Litton's minor children and (c) 214,109 shares issuable pursuant to stock options exercisable within 60 days of March 31, 2018.
- (10) Represents 123,438 shares issuable to Ms. Sandoval pursuant to stock options exercisable within 60 days of March 31, 2018.
- (11) Represents (a) 831 shares held directly by Dr. Smith and (b) 332,653 shares issuable pursuant to stock options exercisable within 60 days of March 31, 2018.
- (12) Represents (a) 282,190 shares held by The Dow Family Trust, for which Mr. Dow serves as a trustee and (b) 36,350 shares issuable pursuant to stock options exercisable within 60 days of March 31, 2018.
- (13) Represents 50,000 shares issuable to Mr. Carter pursuant to stock options exercisable within 60 days of March 31, 2018.
- (14) Represents 50,001 shares issuable to Mr. Cleveland pursuant to stock options exercisable within 60 days of March 31, 2018.
- (15) Represents (a) 9,628 shares held directly by Dr. Montgomery and (b) 68,166 shares issuable pursuant to stock options exercisable within 60 days of March 31, 2018.
- (16) Includes (a) 2,810,429 shares held by Delphi Ventures VII, L.P., (b) 28,103 shares held by Delphi BioInvestments VII, L.P. (together, the Delphi Funds ) and (c) 36,350 shares issuable to Dr. Pakianathan pursuant to stock options exercisable within 60 days of March 31, 2018. The general partner of each of the Delphi Funds is Delphi Management Partners VII, L.L.C. ( DMP VII ). The managing members of DMP VII are Deepika R. Pakianathan, James J. Bochnowski, David L. Douglass and Douglas A. Roeder. DMP VII and each of the foregoing managing members may be deemed a beneficial owner of the reported shares but each of disclaims beneficial ownership except to the extent of any indirect pecuniary interest therein. The address for all entities and individuals affiliated with Delphi Ventures is 3000 Sand Hill Road, Building 1, Suite 135, Menlo Park, CA 94025.
- (17) Represents 36,350 shares issuable to Dr. Preston pursuant to stock options exercisable within 60 days of March 31, 2018. Dr. Preston, a member of our Board of Directors, is a TPG Partner. Dr. Preston has no voting or investment power over and disclaims beneficial ownership of the shares held by TPG Biotechnology Partners II, L.P. The address of Dr. Preston is c/o TPG Global, LLC, 301 Commerce Street, Suite 3300, Fort Worth, TX 76102.
- (18) Represents (a) 31,714 shares held directly by Dr. Siegall and (b) 68,165 shares issuable pursuant to stock options exercisable within 60 days of March 31, 2018.
- (19) Represents (a) 5,000 shares held directly by Ms. Yarno and (b) 25,833 shares issuable to Ms. Yarno pursuant to stock options exercisable within 60 days of March 31, 2018.

(20) Represents (a) 10,129,968 shares held by our current directors and executive officers, (b) 1,724,574 shares issuable pursuant to stock options exercisable within 60 days of March 31, 2018 and (c) 302,540 shares issuable upon conversion of Class A-1 Preferred Stock within 60 days of March 31, 2018, as further described in footnote 1 above.

**Table of Contents**

**SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE**

Section 16(a) of the Exchange Act requires the Company's directors and executive officers, and persons who own more than ten percent of a registered class of the Company's equity securities, to file with the SEC initial reports of ownership and reports of changes in ownership of common stock and other equity securities of the Company. Officers, directors and greater than ten percent stockholders are required by SEC regulation to furnish the Company with copies of all Section 16(a) forms they file.

To the Company's knowledge, based solely on a review of the copies of such reports furnished to the Company and written representations that no other reports were required, during the year ended December 31, 2017, all Section 16(a) filing requirements applicable to its officers, directors and greater than ten percent beneficial owners were complied with.

**Table of Contents****EXECUTIVE OFFICERS**

The following table sets forth certain information with respect to our executive officers as of March 31, 2018. Biographical information with regard to Mr. Cleveland is presented under *Proposal No. 1 Election of Directors* in this proxy statement.

<b>Name</b>	<b>Age</b>	<b>Position(s)</b>
John A. Latham, Ph.D.	58	Chief Scientific Officer
Mark J. Litton, Ph.D..	50	Chief Business Officer, Treasurer and Secretary
Elisabeth A. Sandoval, M.B.A.	56	Chief Commercial Officer and Executive Vice President of Corporate Strategy
Erin Lavelle	40	Chief Operating Officer
Eric G. Carter, Ph.D., M.D.	66	Interim Chief Medical Officer
Jeffrey T.L. Smith, M.D., FRCP	58	Managing Director of Alder BioPharmaceuticals Limited
Larry K. Benedict	57	Executive Vice President and Principal Accounting Officer
Randal A. Hassler	60	Executive Vice President, Pharmaceutical Operations
James B. Bucher, J.D.	52	Senior Vice President and General Counsel

*John A. Latham, Ph.D.* Dr. Latham has served as our Chief Scientific Officer since he co-founded the Company, which commenced operations in January 2004. From 1998 to 2004, Dr. Latham served as a director, senior director, and most recently as Vice President of Gene Function and Target Validation for Celltech Group plc. In 1994, Dr. Latham joined Darwin Molecular Corporation, a first-generation gene-to-drug biotechnology company, as a founding director, where he served from 1994 to 1998. Dr. Latham was one of the early scientists hired by Gilead Sciences, Inc., a biopharmaceutical company, and, from 1989 to 1994, he was a member of a core group established to exploit novel oligonucleotide-based technologies. Dr. Latham holds a Ph.D. in Biochemistry from Massachusetts Institute of Technology and a B.S. in Chemistry from Colorado State University.

*Mark J. Litton, Ph.D.* Dr. Litton has served as our Chief Business Officer, Treasurer and Secretary since he co-founded the Company, which commenced operations in January 2004. From 1999 to 2004, Dr. Litton served as Vice President of Business Development for Celltech Group, where he was responsible for securing, commercializing and partnering numerous novel discoveries and therapeutic opportunities. In 1999, Dr. Litton joined Celltech Group as an employee of Chiroscience Group plc and was later promoted to Vice President Business Development after Chiroscience's merger with Celltech Group in 1999. From 1997 to 1999, Dr. Litton served as the Manager of Business Development for Ribozyme Pharmaceuticals Inc., currently Sirna Therapeutics, Inc., a biopharmaceutical company and wholly-owned subsidiary of Alnylam Pharmaceuticals, Inc., where he helped form relationships with Eli Lilly and Company, Roche Bioscience and GlaxoWellcome plc, currently GlaxoSmithKline plc, a biopharmaceutical company. From 1991 to 1994, Dr. Litton served as a research associate for DNAX Research Institute, a research facility of Schering-Plough, now Merck & Co., a publicly-traded pharmaceutical company. Dr. Litton holds a Ph.D. in Immunology from Stockholm University, an M.B.A. from Santa Clara University and a B.S. in Biochemistry from the University of California, Santa Cruz.

*Elisabeth A. Sandoval, M.B.A.* Ms. Sandoval has served as our Chief Commercial Officer and Executive Vice President of Corporate Strategy since January 2018, and prior to that served as our Chief Commercial Officer from August 2016 to January 2018. From March 2012 to October 2015, Ms. Sandoval served as the Chief Commercial Officer for Kythera Biopharmaceuticals Inc., a biopharmaceutical company. From 2010 to 2012, she served as Vice President of Global Marketing and Strategy at Bausch & Lomb Incorporated, an eye health product company. From 1988 to 2010, she held various roles at Allergan plc, including Global Vice President, Strategic Marketing and Senior

Director of Global Strategic Marketing, which included sales management and marketing leadership for multiple products including Botox for neurological and other disorders. She began her career in research and development at Johnson & Johnson's Ethicon division. Ms. Sandoval holds an M.B.A. from Pepperdine University and a B.S. in Biology from the University of California, Irvine.



---

**Table of Contents**

*Erin Lavelle.* Ms. Lavelle has served as our Chief Operating Officer since April 2018. From October 2017 to March 2018, Ms. Lavelle served as the General Manager of the Taiwan affiliate of Amgen Inc., a biopharmaceutical company. From June 2016 to September 2017, Ms. Lavelle served as Executive Director, Japan and Asia-Pacific Commercial Excellence and Digital Health at Amgen. From July 2003 to June 2016, Ms. Lavelle served in roles of increasing responsibility at Amgen, including as Amgen's Executive Director in the areas of Global Marketing; Global Commercial Finance; and Strategy and Corporate Development. She began her career in 1998 as an investment banker in the healthcare group at Merrill Lynch & Co. Ms. Lavelle holds a B.A. in Economics from Yale University.

*Eric G. Carter, M.D., Ph.D.* Dr. Carter has served as our Interim Chief Medical Officer since April 2018. From 2011 to 2015, Dr. Carter served as senior vice president, chief medical officer, and global head of clinical and non-clinical development of Allergan, plc, a pharmaceutical company, through a period of significant growth until its acquisition by Actavis Pharmaceuticals in 2015. Prior to Allergan, Dr. Carter served as chief scientific officer, head of research and development, and chief medical officer of King Pharmaceuticals from 2007 until the company was acquired by Pfizer, Inc. in 2011. From 2001 to 2007, he worked for GlaxoSmithKline, in positions of increasing responsibility within the global clinical development and medical affairs areas. After serving in academia at the University of North Carolina School of Medicine, the UCLA Fielding School of Public Health, and the University of California, Berkeley, Dr. Carter began his pharmaceutical career at Pharmacia Corporation, a pharmaceutical company, in 1993. Dr. Carter serves on the Board of Directors of Adverum Biotechnologies, Inc., a biotechnology company, and he currently serves as the chair of the scientific advisory board at Bioniz Therapeutics. Dr. Carter holds a B.Sc. in Biochemistry from the University of London, a Ph.D. in Biochemistry from the University of Cambridge, and an M.D. from the University of Miami School of Medicine.

*Jeffrey T.L. Smith, M.D., FRCP.* Dr. Smith has served as our Managing Director of Alder Biopharmaceuticals Limited since March 2017. Dr. Smith previously served as our Senior Vice President, Translational Medicine from 2012 to March 2017 and in other senior management positions from April 2004 to 2012. From 1999 to 2004, Dr. Smith served as Senior Director of Medical Research for Celltech R&D, where he was responsible for planning and managing the CDP870 anti-TNF clinical trials for RA as well as several other key autoimmune clinical development programs. From 1997 to 1999, Dr. Smith served as Medical Director at Simbec Research Ltd., a contract research organization. From 1995 to 1997, Dr. Smith served as Head of Clinical Pharmacology at Hoechst Marion Roussel Ltd., a pharmaceutical company. From 1994 to 1995, Dr. Smith served as a Senior Clinical Physician at the Proctor and Gamble Company, a publicly-traded consumer products company, and from 1989 to 1994, he served as a Senior Research Physician in the clinical pharmacology department at Glaxo Research and Development Ltd., now a division of GlaxoSmithKline plc. Dr. Smith holds an M.D. from the University of London and is a Fellow of the Royal College of Physicians in London.

*Larry K. Benedict.* Mr. Benedict has served as our Executive Vice President and Principal Accounting Officer since October 2016, and prior to that served as our Senior Vice President of Finance from January 2013 to October 2016 and as our Vice President of Finance from June 2008 to January 2013. From 2000 to 2008, Mr. Benedict served in various positions at Seattle Genetics, Inc., most recently as Director of Finance and Controller. Mr. Benedict holds a B.S. in Accounting from Central Washington University.

*Randal A. Hassler.* Mr. Hassler has served as our Executive Senior Vice President of Pharmaceutical Operations since February 2018, and prior to that served as our Senior Vice President of Pharmaceutical Operations from August 2014 to February 2018. From 2008 to 2014, Mr. Hassler served in various leadership positions at Seattle Biomedical Research Institute, a non-profit infectious disease research institute, most recently as Chief Operating Officer. From 1995 to 2007, he served in various leadership positions at Amgen Inc., a biopharmaceutical company, including Process Development, Quality Control, and Quality Assurance. From 1983 to 1995, Mr. Hassler served in a variety of research and development positions at Synergen Inc., a biotechnology company, which was acquired by Amgen in

1994. Mr. Hassler holds a B.S. in Microbiology from Indiana University and an M.S. in Microbiology from Colorado State University.

**Table of Contents**

*James B. Bucher, J.D.* Mr. Bucher has served as our Senior Vice President and General Counsel since January 2016. During 2015, Mr. Bucher served as a consultant providing legal services to several life sciences companies. From 2007 to 2014, Mr. Bucher served as Vice President, Corporate Legal Affairs and Secretary, and as the Corporate Compliance Officer, of Exelixis, Inc., a biopharmaceutical company. From 1991 to 2007, Mr. Bucher practiced as a corporate attorney at the international law firm Shearman & Sterling LLP, becoming a partner in 2001. Mr. Bucher holds a J.D. with distinction from Emory University School of Law and a B.A. in Biology from Colgate University.

**Table of Contents**

**EXECUTIVE COMPENSATION**

**COMPENSATION DISCUSSION AND ANALYSIS**

Our compensation discussion and analysis discusses the total compensation for our Chief Executive Officer, Executive Vice President and Principal Accounting Officer and our three other most highly compensated executive officers during the year ended December 31, 2017, which officers are referred to as our named executive officers. Our named executive officers are:

Randall C. Schatzman, Ph.D., Former President, Chief Executive Officer and Director;

Larry K. Benedict, Executive Vice President and Principal Accounting Officer;

John A. Latham, Ph.D., Chief Scientific Officer;

Elisabeth A. Sandoval, M.B.A., Chief Commercial Officer and Executive Vice President of Corporate Strategy; and

Jeffrey T.L. Smith, M.D., FRCP, Managing Director of Alder BioPharmaceuticals Limited.

Our compensation discussion and analysis describes our overall executive compensation philosophy, objectives and practices, as well as the Compensation Committee's decisions and determinations regarding executive compensation for 2017.

**Executive Summary**

The Compensation Committee's basic responsibility is to review the performance of our executive officers in achieving corporate and individual goals and objectives and to ensure that our management is compensated effectively in a manner consistent with our compensation philosophy and competitive practice. Toward that end, the Compensation Committee oversees and reviews all of our management compensation, equity and employee benefit plans and programs, which include our 2014 Equity Incentive Plan, or the 2014 Plan, and the 2014 Employee Stock Purchase Plan, or the ESPP.

The goal of our Compensation Committee is to ensure that our compensation programs are aligned with the interest of our stockholders and our corporate goals and the total compensation paid to each of our named executive officers is fair, reasonable and competitive. Key elements of our compensation programs include:

base salary, to enable us to attract and retain the talent needed to meet our corporate objectives;

an annual cash bonus program, tied to the achievement of corporate and individual performance goals; and

equity incentive compensation, which is provided to all employees, is typically subject to multi-year vesting based on continued service and is in the form of stock options, the value of which depends on the performance of our common stock price, in order to align employee interests with those of our stockholders over the longer-term.

The Compensation Committee believes that our executive compensation program is appropriately designed and reasonable in light of the executive compensation programs of our peer group companies and responsible in that it both encourages our executive officers to work for meaningful stockholder returns and reflects a pay-for-performance philosophy, without encouraging our employees to assume excessive risks.

The highlights of our company performance for 2017 include:

Positive results in our Prevention Of Migraine via Intravenous ALD403 Safety and Efficacy 1 (PROMISE 1) Phase 3 clinical trial, a pivotal clinical trial evaluating the safety and efficacy of

**Table of Contents**

eptinezumab administered via infusion once every 12 weeks for one year in approximately 888 patients with frequent episodic migraine patients:

Met the primary endpoint with highly statistically significant reductions in monthly migraine days in the trial following the first quarterly infusion.

Significant clinical benefit achieved on Day One post-infusion ( $p=0.0087$  unadjusted) and significant 50 percent ( $p=0.0001$ ) and 75 percent ( $p=0.0007$ ) responder rates month one through month three.

Efficacy further improved following a second quarterly infusion; an average of 17% of patients had no migraines following the first administration and that rose to 26% of patients following the second administration.

The safety profile was similar to placebo and consistent with previously reported eptinezumab studies.

Eptinezumab data presentations at top tier medical conferences highlighted Phase 2b (chronic migraine) and PROMISE 1 Phase 3 (episodic migraine) clinical data and analyses:

Three scientific presentations at the 69th Annual American Academy of Neurology (AAN) in April 2017.

Four scientific presentations at the 59th Annual Scientific Meeting of the American Headache Society (AHS) in June 2017.

Seven scientific presentations at the 18th Congress of the International Headache Society (IHC) in September 2017.

We completed a public offering of common stock on July 18, 2017, resulting in net proceeds to us of approximately \$161.5 million, after underwriting discounts, commissions and offering expenses.

Our executive compensation policies for 2017 included the following:

The majority of our compensation was linked to performance: 83.8% of the compensation of our Chief Executive Officer was performance based, consisting of at-risk incentive compensation in the form of a bonus and equity awards; an average of 71.9% of the compensation of our other Named Executive Officers was performance based.

The goals under our annual incentive compensation bonus plan includes goals that drive the long-term advancement of our clinical and pre-clinical development programs.

The incentive compensation bonus for our Chief Executive Officer was based 100% on attainment of our corporate goals, aligning the interest of our Chief Executive Officer with our stockholders' interest.

Our equity incentive compensation, consisting of stock options, vest over a multi-year period based on continued service.

Our change in control severance benefits generally require a double-trigger, meaning that a Named Executive Officer is only paid in connection with a change in control if his or her employment is involuntarily terminated other than cause, death or disability or if the participant resigns for good reason.

We do not provide fringe benefits to our Named Executive Officers, such as car allowances, financial planning advice or club memberships.

Approximately 99% of the votes cast in the stockholder advisory vote on the compensation of our Named Executive Officers in 2017 approved our executive compensation as described in our 2017 definitive proxy statement.

## Table of Contents

### **Compensation Philosophy and Objectives**

We are a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform the treatment paradigm in migraine. Our compensation philosophy is to provide overall compensation that is competitive among comparable companies in our industry in order to attract and retain the highest quality executive officers and other senior management.

The Compensation Committee believes that, when targeted levels of performance are achieved, the resulting overall compensation should be comparable with the pay practices of a peer group of companies selected by the Compensation Committee and other market data. The Compensation Committee generally seeks to establish a mix between cash compensation and long-term equity incentives similar to the mix utilized by the companies in our peer group.

Our executive compensation consists of the following components:

base salary, to enable us to attract and retain the talent needed to meet our corporate objectives;

an annual cash bonus program, tied to the achievement of corporate and, in the case of our non-Chief Executive Officer named executive officers, individual performance goals; and

equity incentive compensation, which is provided to all employees, is typically subject to multi-year vesting based on continued service and is in the form of stock options, the value of which depends on the performance of our common stock price, in order to align employee interests with those of our stockholders over the longer-term.

Our Compensation Committee believes that it is important to align compensation levels and the mix of compensation to that offered by our peers in order to attain our primary compensation objectives – retaining, incentivizing and attracting the high-quality executives whose efforts are key to our long-term success.

At the time the Compensation Committee makes executive compensation decisions, the Compensation Committee reviews individual performance and our company's performance against pre-established company corporate and strategic goals. In this regard, decisions with respect to the principal, ongoing elements of compensation for our executive officers are based, in combination with the competitive peer group analysis described above, upon the Compensation Committee's assessment of (i) each individual's performance as assessed by our CEO (other than with respect to his own performance) in consultation with the Compensation Committee and (ii) our performance measured against corporate and strategic goals as defined by the Compensation Committee.

Determinations of individual performance at the executive officer level are based on achievement of individual goals, as well as the individual's performance with respect to (and contributions toward) the achievement of our pre-established corporate and strategic goals. The Compensation Committee believes that successful execution against goals is the best way to enhance long-term stockholder value.

The Compensation Committee generally relies upon its judgment and not upon rigid guidelines or formulas in determining the amount and mix of compensation elements for each executive officer, particularly with respect to base salary determinations and overall levels of long-term equity compensation. However, as set forth below, bonus awards



under our annual bonus program are formulaic in that the target bonus opportunity is established, as is the extent to which bonuses are awarded based on individual performance against individual goals and the achievement of pre-established corporate goals. Factors considered by the Compensation Committee in making its determinations include individual performance, contributions to corporate and strategic goals, and the nature and scope of the individual's responsibilities and effectiveness in leading management's initiatives to achieve the corporate goals. The Compensation Committee also periodically consults with executive compensation consultants and, in 2017, considered the compensation levels of similarly positioned executives at the peer group companies discussed below in determining the mix of compensation elements for the executive officers. Our peer

**Table of Contents**

group companies are selected based on a review of biotechnology and pharmaceutical companies that are similar to Alder with respect to industry, development stage, market capitalization, headcount as well as revenue and funding from partnerships. Based on information available as of January 2017, all of our peer group companies were in the biotechnology or pharmaceuticals industry and 17 of our peer group companies did not have a marketed product and were in Phase 2, Phase 3 or NDA phase of development. The median market capitalization of our peer group companies was \$1.4 billion, compared to Alder's market capitalization as of December 31, 2016 of \$1.3 billion, and the median headcount was 208 employees, compared to Alder's 176.

The Compensation Committee reviews the peer group periodically to reflect changes in development stage, market capitalization and other factors, including acquisitions, and revises the companies included in the peer group accordingly, based upon the advice of Compensia. Considering the growth in our market capitalization and advancement of our pipeline, our Compensation Committee reviewed and revised our peer group in January 2017 to consist of:

Accelaron Pharma, Inc.	Clovis Oncology, Inc.	Ophotech Corporation
Achillion Pharmaceuticals, Inc.	Epizyme, Inc.	Portola Pharmaceuticals, Inc.
Acorda Therapeutics, Inc.	Ironwood Pharmaceuticals, Inc.	PTC Therapeutics, Inc.
Agios Pharmaceuticals, Inc.	Intercept Pharmaceuticals, Inc.	Radius Health, Inc.
ARIAD Pharmaceuticals, Inc.	Juno Therapeutics, Inc.	Relypsa Inc.
Array BioPharma Inc.	MacroGenics, Inc.	Sage Therapeutics, Inc.
bluebird bio, Inc.	Neurocrine Biosciences, Inc.	Ultragenyx Pharmaceutical Inc.
Celldex Therapeutics, Inc.	OncoMed Pharmaceuticals, Inc.	

**Compensation Consultants and Management Participation in Compensation Decisions**

Under its charter, the Compensation Committee has the authority, in its sole discretion, to retain (or obtain the advice of) any compensation consultant, legal counsel or other adviser to assist it in the performance of its duties. The Compensation Committee has consulted with its compensation consultants periodically with respect to specific questions or as new compensation programs are considered and to update its competitive market analysis on an annual basis.

In October 2015, Compensia was first retained by Alder at the request of our Compensation Committee, in consultation with management, to prepare compensation analyses for our executives. In particular, Compensia was directed to provide a market analysis of base salary, annual bonus and long-term incentive compensation of our executive officers against our revised peer group. This market analysis was reviewed again with the Compensation Committee in January 2017, and was used to guide decisions made in January 2017 regarding base salary adjustments, annual target bonus incentive opportunities and long-term equity compensation. Our CEO makes recommendations to the Compensation Committee with respect to base salary levels, annual bonus targets, individual performance assessments and the levels of long-term equity compensation to be awarded to our other executive officers in consultation with our compensation consultants but the Compensation Committee approves of any adjustments as the

committee sees appropriate. Compensia provided competitive market data and identified where our executives were compensated inconsistently with our peer companies.

On an annual basis, our Compensation Committee analyzes whether the work of such consultant as a compensation consultant has raised any conflict of interest, taking into consideration the following factors: (i) the provision of other services to our company by Compensia; (ii) the amount of fees from our company paid to Compensia as a percentage of the firm's total revenue; (iii) Compensia's policies and procedures that are designed to prevent conflicts of interest; (iv) any business or personal relationship of such consultant or the individual compensation advisors employed by the firm with an executive officer of our company; (v) any business or personal relationship of the individual compensation advisors with any member of the Compensation Committee; and (vi) any stock of our company owned by the individual compensation advisors employed by the firm. The Compensation Committee determined, based on its analysis of the above factors, that the work of

## **Table of Contents**

Compensia and the individual compensation advisors employed by Compensia as compensation consultants to our company has not created any conflict of interest. The Compensation Committee will continue to assess the independence of any of its compensation advisers by reference to the foregoing factors, consistent with applicable Nasdaq listing standards.

### **Results of Most Recent Stockholder Advisory Vote on Executive Compensation**

Approximately 99% of the votes cast in the stockholder advisory vote on the compensation of our Named Executive Officers in 2017 approved our executive compensation as described in our 2017 definitive proxy statement. The Compensation Committee considered the result of the stockholder advisory vote as an endorsement of its compensation policies, practices and philosophy for our Named Executive Officers. Accordingly, the Compensation Committee determined not to make any significant changes as a result of the vote. In addition, in part based on the support shown by the vote, the Compensation Committee has maintained a consistent approach in making compensation decisions.

The Compensation Committee considers the results of the say-on-pay vote on our executive compensation program as part of its annual executive compensation review. Our Board of Directors values the opinions of our stockholders, and the Compensation Committee will continue to consider the outcome of future say-on-pay votes, as well as any feedback received throughout the year, when making compensation decisions for the Named Executive Officers. The next say-on-pay vote on the compensation of the Named Executive Officers will take place at the Annual Meeting.

### **Principal Elements of Compensation**

*Base Salaries.* Base salaries are established to attract and retain talented executive personnel. Base salaries for our Chief Executive Officer and the other executive officers are established based on the underlying scope of their respective responsibilities, taking into account competitive market compensation by reviewing the base salaries paid by our peer group for similar positions. The base salary for each executive officer is generally targeted on an annual basis to be between the 25th and 75th percentiles for similarly positioned executives based on the data from our peer group. We also review industry survey data provided by our compensation consultants. Annual salary adjustments are based primarily on a review of the competitive market salaries and general levels of market increases in salaries of similarly positioned executives in our peer group, and adjusted based on individual performance, achievement of our corporate goals, changes in job duties and responsibilities and budget considerations, as applicable. Annual salary adjustments are typically reviewed in January of each year.

*Annual Incentive Compensation.* Our executive officers are eligible to participate in our bonus program, based upon individual performance and the achievement of corporate goals and other factors deemed relevant by our Compensation Committee. Corporate goals for 2017 related to clinical development and manufacturing of eptinezumab, activities related to the planned commercialization of eptinezumab, research and development, capital raising, and business development. The Compensation Committee determines the relative achievement of the specific corporate goals following the end of the year. The Compensation Committee also has the discretion to take into account significant corporate events or other significant accomplishments that were not contemplated at the beginning of the performance period in determining the relevant corporate and individual achieved performance percentages for the relevant year. Our Chief Executive Officer assesses the other executives' contributions to the corporate goals, and makes a recommendation to the Compensation Committee with respect to such individual's achieved performance percentage and the Compensation Committee then makes a final determination of the individual performance percentage. Neither our Chief Executive Officer or any executive officer take part in the Compensation Committee's decisions regarding executive officer compensation. The weighted company performance percentage and individual performance percentage are then multiplied by a base pay target percentage for each executive officer to determine the

actual amount of the bonus award. The target incentive bonus percentage for each executive officer is determined by the Compensation Committee at the beginning of the year and is based on a review of potential bonuses for similarly positioned executives at

**Table of Contents**

companies included in our peer group. These target percentages are reviewed on an annual basis and adjusted based on the results of competitive market data provided by the Compensation Committee's compensation consultant but are generally set near the 50th percentile for annual cash bonus targets for similar positions. For 2017, the Compensation Committee determined the following target bonus percentages:

<b>Title (Name)</b>	<b>Target Percentage of Base Salary</b>
Former President and Chief Executive Officer (Dr. Schatzman)	55%
Chief Scientific Officer (Dr. Latham) and Chief Commercial Officer and Executive Vice President of Corporate Strategy (Ms. Sandoval)	40%
Executive Vice President and Principal Accounting Officer (Mr. Benedict) and Managing Director of Alder BioPharmaceuticals Limited (Dr. Smith)	35%

Our company's achieved performance percentage and/or the individual achieved performance percentage may exceed 100% in the event we and/or the executive officer exceed expected performance against goals.

For the executive officers, other than Dr. Schatzman, the final performance percentage during 2017 was based 50% on company performance and 50% on the individual's performance. Dr. Schatzman's final performance percentage was determined by the Compensation Committee based solely on overall achievement of corporate goals. The Compensation Committee determined that greater weighting of the corporate goals should apply to our CEO than our other executive officers because his positions and responsibilities give him more opportunity to significantly impact our overall corporate performance.

In making its assessment regarding the extent to which the pre-established corporate performance measures for that year have been achieved, the Compensation Committee considers both the extent to which the corporate performance measures were achieved as well as the relative importance of the corporate performance measures that were achieved as compared to any corporate performance measures that were not achieved. The Compensation Committee then assesses our performance on an overall basis. Because the corporate performance measures include stretch goals and vary in terms of relative importance to Alder, the Compensation Committee has not historically given specific weightings to the various corporate performance measures when initially established. Accordingly, the corporate performance percentage determined by the Compensation Committee in any given year may be either greater or less than the percentage of the total corporate objectives for that year that were actually fully achieved. The corporate performance measures used for 2017 were primarily based on the advancement of development and clinical activities related to eptinezumab, which the Compensation Committee believes strongly relate to the creation of total stockholder value, as eptinezumab is our lead product candidate. Alder's corporate goals in 2017 were:

With regard to eptinezumab:

Report top-line PROMISE 1 12 and 24 week data by the end of the second quarter of 2017;

Complete recruiting of PRevention Of Migraine via Intravenous ALD403 Safety and Efficacy 2 (PROMISE 2) clinical trial, our Phase 3 pivotal trial evaluating the safety and efficacy of eptinezumab

Edgar Filing: ALDER BIOPHARMACEUTICALS INC - Form DEF 14A

administered via infusion once every 12 weeks for six months in approximately 1,050 patients with chronic migraine by the end of the fourth quarter of 2017;

Complete recruiting of a one-year open label safety study by the end of the second quarter of 2017;

Initiate a clinical study in support of a potential BLA submission to the U.S. Food and Drug Administration ( *FDA* );

Finalize the plan for transition of drug supply to commercial manufacturers and initiate the appropriate study or studies for inclusion in the Biologics License Application ( *BLA* ) submission to the FDA;

Complete a plan for an alternate route of administration;

**Table of Contents**

Manufacture eptinezumab to enable completion of planned clinical trials;

Complete a successful CMC meeting with the FDA before the end of the second quarter of 2017; and

Initiate validation lot campaigns for potential commercial manufacturing;

Advance commercial readiness and take other actions in advance of potential commercialization of eptinezumab.

With regard to our pre-clinical programs:

Progress ALD1910, including completion of manufacturing process transfer and initiation of IND-enabling acute toxicology studies; and

Nominate a new target for pipeline before the end of 2017.

With regard to our corporate activities:

Complete an offering raising at least \$350 million at a valuation approved by the Board; and

Explore partnership opportunities for our product candidates.

In reviewing the year, our Compensation Committee concluded that 2017 was a year of strong company performance and that we performed well against our corporate goals. While the Compensation Committee did not establish specific weightings to the various corporate performance measures, the Compensation Committee prioritized the achievement of goals related to the development of eptinezumab. In particular, the Compensation Committee noted:

With regard to eptinezumab:

We successfully completed reported top-line data from our PROMISE 1 clinical trial in June 2016;

We completed recruiting in our PROMISE 2 trial a full quarter ahead of our plan;

We recruited our one-year open label safety study a full quarter ahead of plan;



We captured data in PROMISE 2 which was highly significant and differentiated from competition, allowing us to propose having it in our final label;

The FDA approved our investigational new drug (IND) amendment allowing us to transition our initial commercial supply of eptinezumab into humans;

We worked with our suppliers to manufacture drug required for all pivotal clinical trials (with additional back up) on time;

We held a successful end of Phase 2 meeting with the FDA in May 2017;

We agreed to path forward for commercial supply chain; and

We successfully executed validation lot campaign at our commercial supplier one quarter ahead of schedule.

With regard to our pre-clinical programs:

We made significant progress in advancing ALD1910.

With regard to our corporate activities:

We completed a public offering of common stock on July 18, 2017, resulting in net proceeds to us of approximately \$161.5 million, after underwriting discounts, commissions and offering expenses;

**Table of Contents**

We made progress toward an additional financing, which closed in 2018; and

We made significant progress in advancing the terms of a European patent settlement and global license agreement with Teva Pharmaceuticals International GmbH ( *Teva GmbH* ), which we entered into in January 2018.

As a result, our Compensation Committee determined that we met or exceeded substantially all of our corporate goals for 2017. Consequently, the Compensation Committee determined our corporate performance percentage to be 115% for 2017. Individual bonus determinations for 2017 are discussed in more detail under the heading *Compensation Discussion and Analysis 2017 Compensation Decisions* below.

*Long-Term Incentive Compensation.* Long-term incentive compensation in the form of equity awards is designed to provide executive officers with meaningful compensation awards in order to align executives' incentives with stockholder value creation. Generally, significant stock awards are made at the time an executive officer commences employment. Thereafter, stock awards may be made at varying times and in varying amounts in the discretion of the Compensation Committee, but are generally made once a year unless such executive officer is promoted, in which case an award will normally be made at that time, or for recognition of outstanding performance. Upon hiring an executive officer, stock awards generally will be made at the next regularly scheduled Board or Compensation Committee meeting. Annual stock awards to all executives are made at regularly scheduled meetings of the Compensation Committee and are generally made in January. Alder does not have any program, plan or practice to time stock awards to its executives or other employees in coordination with the release of material, non-public information.

We grant equity awards to our executive officers by delivering stock options and allowing our executive officers to participate in our ESPP.

In connection with the annual review of each executive officer's individual performance and consistent with our compensation philosophy, in January 2017, our Compensation Committee approved annual equity incentive awards for our named executive officers serving at that time based on a comparative analysis of comparable positions at our peer group companies. The annual incentive awards granted to our Named Executive Officers under our 2014 Plan are set forth in the table below:

<b>Title (Name)</b>	<b>Option Award</b>
Former President and Chief Executive Officer (Dr. Schatzman)	275,000
Chief Scientific Officer (Dr. Latham)	95,000
Managing Director of Alder BioPharmaceuticals Limited (Dr. Smith)	85,000
Chief Commercial Officer and Executive Vice President of Corporate Strategy (Ms. Sandoval)	75,000
Executive Vice President and Principal Accounting Officer (Mr. Benedict)	50,000

In December 2017, in connection with certain of our executive officers assuming greater leadership positions and responsibilities related to key corporate activities, our Compensation Committee approved additional equity incentive awards under our 2014 Plan as set forth in the table below:

<b>Title (Name)</b>	<b>Option Award</b>
Chief Scientific Officer (Dr. Latham)	75,000
Managing Director of Alder BioPharmaceuticals Limited (Dr. Smith)	50,000
Chief Commercial Officer and Executive Vice President of Corporate Strategy (Ms. Sandoval)	150,000

## **Table of Contents**

We do not have stock ownership guidelines for our executive officers because a significant portion of officer compensation is already performance-based, in particular our equity incentive awards. We believe this compensation sufficiently aligns the incentives of our executives with our stockholders.

The exercise price of our stock options is always equal to the fair market value (our closing price on the Nasdaq Global Market) of our common stock on the date of grant. Our stock option grants generally vest 1/4th upon the one year anniversary of the grant date and 1/36th of the remaining shares each month thereafter until such grant is fully vested on the four year anniversary of the grant date, subject to vesting acceleration as described under the heading Compensation Discussion and Analysis Post-Termination Protection below. The vesting schedule and the number of shares granted are established to ensure a meaningful retention incentive. Accordingly, the stock option will provide a return to the employee only if he or she remains in our service and only if the market price of our common stock appreciates over the option term.

### **Post-Termination Protection**

We do not have a severance plan for employees generally. However, we adopted an Executive Severance Benefit Plan, or the Severance Plan, which became effective in May 2014. The Severance Plan was amended and restated in December 2016, primarily to cover the employment by our executive officers by a subsidiary of the Company. Our Severance Plan provides for the payment of severance benefits to certain eligible employees of our company in the event such persons become subject to involuntary or constructive employment terminations. Benefits under the Severance Plan are provided to our chief executive officer, executive officers and key employees designated by the Board of Directors and who sign a participation notice. Payments under the Severance Plan will be reduced by any severance benefit payable to a participant under any other severance plan, program or agreement. The principal features of our Severance Plan as it applies to participants are summarized below.

#### *Non-Change in Control Severance Benefits*

Under the terms of the Severance Plan, in the event we involuntarily terminate any participant for any reason other than cause, death or disability, and such termination is not in connection with or within 12 months following a change in control, if the participant timely executes a release of claims and continues to comply with all restrictive covenant agreements, the participant would be entitled to: (1) an amount equal to the sum of the participant's monthly base salary and pro-rated annual target bonus, multiplied by 18, in the case of our chief executive officer, and between six and 12 in the case of all other participants; and (2) payment by us of COBRA premiums to continue health insurance coverage for the participant and his eligible dependents for a period of up to 18 months, in the case of our chief executive officer, and between six and 12 months in the case of all other participants. The cash severance and payments of COBRA premiums would be paid in equal installments on Alder's regular payroll schedule over the applicable severance period, less applicable withholdings and deductions.

For non-chief executive officer participants, for both Non-Change in Control and Change in Control termination situations, the applicable multiple to be used in determining the amount of cash severance and the number of months during which COBRA continuation coverage will be available is determined as: six plus one for each full year of service with us, up to a maximum of 12.

#### *Change in Control Severance Benefits*

Under the Severance Plan, in the event we involuntarily terminate any participant for any reason other than cause, death or disability, or the participant resigns for Good Reason, and such termination or resignation occurs in connection with or within 12 months following a change in control, then if the participant timely executes a release of

claims and continues to comply with all restrictive covenant agreements, the participant generally would be entitled to the following payments and benefits: (1) a single lump sum payment equal to the sum of the participant's monthly base salary and monthly annual target bonus, multiplied by 18 in the case of our chief executive officer, and between six and 12 in the case of all other participants; (2) payment of COBRA premiums to continue health insurance coverage for the participant and his eligible dependents for a period of up to 18 months, in the case of our chief executive officer, and between six and 12 months in the case of all other

## Table of Contents

participants; and (3) 100% of the shares of our common stock underlying all unvested stock options held by such participant immediately prior to such termination of employment will fully vest and become exercisable, if applicable, on the date of such termination (and if applicable, any acquisition or repurchase rights held by us or any successor corporation with respect to such stock awards will lapse in full on the date of such termination). In addition, 100% of the outstanding and unvested stock options will fully vest and become exercisable if the options are not assumed or substituted for in a change in control or, with respect to the chief executive officer, the participant remains employed through the one-year anniversary of the change in control.

### *Definitions*

For purposes of the Severance Plan, a *cause* includes, but is not limited to, the following: (1) employee's continued failure, in the reasonable opinion of the Board of Directors, to perform one or more assigned duties or responsibilities to the company, such failure being evidenced by a written report submitted on behalf of the company to the Board of Directors so indicating failure and including a remedy or remedies reasonably satisfactory to the Board of Directors for correcting the asserted failure(s); (2) failure to follow the lawful directives of employee's manager(s), such failure being evidenced by a written report submitted by such manager(s) to the Board of Directors so indicating failure and including a remedy or remedies reasonably satisfactory to the Board of Directors; (3) material violation of any company policy; (4) commission of any act of fraud, embezzlement, dishonesty or any other misconduct that has caused or is reasonably expected to result in material injury to the company; (5) unauthorized use or disclosure of any proprietary information or trade secrets of the company or any other party to whom employee owes an obligation of nondisclosure as a result of the relationship with the company; (6) material breach by employee of any obligations under any written agreement or covenant with the company; or (7) conviction of, or plea of *guilty* or *no contest* to, a felony under the laws of the United States or any state.

For purposes of the Severance Plan, a *resignation for good reason* generally means a participant's resignation from all positions he or she then holds with us within 30 days following the expiration of the cure period (described below) following the occurrence of any of the following events taken without such participant's written consent, provided that the participant has given us written notice of the event within 30 days of the first occurrence of such event and has given us at least 30 days to cure the event and, to the extent curable, we have not cured such event within 30 days after receipt of such notice: (1) a material reduction in the participant's annual base salary; (2) a material adverse change in the participant's position causing such position to be of materially reduced status or responsibilities; (3) relocation of the participant's principal place of employment to a place that increases the participant's one-way commute by more than 50 miles as compared to the participant's then-current principal place of employment immediately prior to such relocation; or (4) the failure of any successor-in-interest to assume any of our material obligations under the Severance Plan or material written contractual obligation to the participant, which (in either case) adversely affects the participant.

For purposes of the Severance Plan, a *change in control* means a *change in control* as defined in our 2014 Equity Incentive Plan.

In addition, in the event any of the amounts provided for under the Severance Plan or otherwise would constitute a *parachute payment* within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended, or the Code, and such payments would be subject to the excise tax imposed by Section 4999 of the Code, then such payments will either be (1) provided to the participant in full, or (2) reduced to such lesser amount that would result in a smaller or no portion of such payments being subject to the excise tax, whichever amount, after taking into account all applicable taxes, including the excise tax, would result in the participant's receipt, on an after-tax basis, of the greatest amount of such payments.

We may amend or terminate the Severance Plan or any participation notice at any time provided that a participant's written consent is obtained if the amendment or termination would adversely affect the participant.

All payments and severance benefits under the Severance Plan are subject to recoupment by us under any clawback policy we adopt in accordance with applicable law and certain other recoupment provisions as determined by the Board of Directors.

**Table of Contents**

The Compensation Committee believes these severance benefits are important from a retention perspective to provide some level of protection to our executive officers from being terminated without cause or constructively terminated prior to or after a change in control, and that the amounts are reasonable when compared with similar arrangements adopted by companies in our peer group. In addition, the Compensation Committee believes that these severance benefits align executive and stockholder interests by enabling the executive officers to consider corporate objectives and possible transactions that are in the best interests of the stockholders and other constituents of Alder without undue concern over whether such objectives or transactions may jeopardize the officers' own employment. With these arrangements, the Compensation Committee sought uniformity of results among the officers based on their positions at Alder, with Dr. Schatzman receiving some additional vesting acceleration. In addition, the Compensation Committee believes that the payment-triggering event outside of the death or disability context, namely, being terminated without cause or constructively terminated, and then only when there is no misconduct by the officer, is a fair hurdle for the ensuing rewards. More information regarding these arrangements is provided under the heading Potential Payments upon Termination or Change in Control.

**2017 Compensation Decisions**

*CEO Compensation.* Dr. Schatzman's 2017 compensation consisted principally of base salary, an annual bonus award and an annual stock option award. The Compensation Committee determined his compensation using methods consistent with those described above under the heading Principal Elements of Compensation. In January 2017, the Compensation Committee approved a merit increase of 3.0% to Dr. Schatzman's 2016 base salary, and an additional \$20,000 base salary market increase (to \$560,750 in 2017) in recognition of his role in leading the achievement of substantially all of our 2016 corporate performance goals and an analysis of competitive peer group salary levels and other survey data. The Compensation Committee in February 2018 approved a cash bonus of \$354,674 under our 2017 executive bonus program in accordance with the level of achievement of the pre-defined corporate performance goals for 2017 and set by the Compensation Committee at 115% as described above under the heading Principal Elements of Compensation Annual Incentive Compensation. Dr. Schatzman was awarded a grant of stock options to purchase 275,000 shares in January 2017 in accordance with the methods described above under the heading Principal Elements of Compensation Long-Term Incentive Compensation.

*Compensation of the Other Named Executive Officers.* The Compensation Committee reviewed similar considerations for each of the other named executive officers, and our Compensation Committee's 2017 compensation determination for these executive officers are set forth below.

With respect to Dr. Latham, the Compensation Committee focused on Dr. Latham's key contributions to advancing our clinical and preclinical pipeline and his key role in positioning our intellectual property. In January 2017, the Compensation Committee approved a merit increase of 4.0% to Dr. Latham's 2016 base salary, and an additional \$20,000 base salary market increase, (to \$441,974 in 2017) in recognition of the individual performance described above and an analysis of competitive peer group salary levels and other survey data. The Compensation Committee in February 2018 also approved a cash bonus of \$198,888 under our 2017 executive bonus program in accordance with the level of achievement of the pre-defined corporate performance goals for 2017 (115%) and individual performance (110%) as described above under the heading Principal Elements of Compensation Annual Incentive Compensation. Dr. Latham was awarded a grant of stock options to purchase 95,000 shares in January 2017 in accordance with the methods described above under the heading Principal Elements of Compensation Long-Term Incentive Compensation. In addition, in December 2017, in recognition of Dr. Latham assuming a greater leadership position and responsibilities related to the development of eptinezumab program, Dr. Latham was awarded a grant of stock options to purchase 75,000 shares.



With respect to Ms. Sandoval, the Compensation Committee focused on Ms. Sandoval's key contributions to planning for commercialization of eptinezumab and an analysis of competitive peer group salary levels and other survey data. In January 2017, the Compensation Committee approved a merit increase of 4.0% to Ms. Sandoval's 2016 base salary (to \$385,168 in 2017) in recognition of the individual performance described above and an analysis of competitive peer group salary levels and other survey data. The Compensation Committee in

**Table of Contents**

February 2018 also approved a cash bonus of \$230,288 under our 2017 executive bonus program in accordance with the level of achievement of the pre-defined corporate performance goals for 2017 (115%) and individual performance (115%) as described above under the heading **Principal Elements of Compensation Annual Incentive Compensation**. Ms. Sandoval was awarded a grant of stock options to purchase 75,000 shares in January 2017 in accordance with the methods described above under the heading **Principal Elements of Compensation Long-Term Incentive Compensation**. In addition, in December 2017, in recognition of Ms. Sandoval assuming a greater leadership position and increasing responsibilities, Ms. Sandoval was awarded a grant of stock options to purchase 150,000 shares.

With respect to Mr. Benedict, the Compensation Committee focused on Mr. Benedict's key contributions to our successful public offering in July 2017 and his key role in leading our SEC and financial reporting. In January 2017, the Compensation Committee approved a merit increase of 3.0% to Mr. Benedict's 2016 base salary, and an additional \$17,500 base salary market increase, (to \$343,804 in 2017) in recognition of the individual performance described above and analysis of competitive market salary levels based on survey data. The Compensation Committee in January 2018 also approved a cash bonus of \$129,356 under our 2017 executive bonus program in accordance with the level of achievement of the pre-defined corporate performance goals for 2017 (115%) and individual performance (100%) as described above under the heading **Principal Elements of Compensation Annual Incentive Compensation**. Mr. Benedict was awarded a grant of stock options to purchase 50,000 shares in January 2017 in accordance with the methods described above under the heading **Principal Elements of Compensation Long-Term Incentive Compensation**.

With respect to Dr. Smith, the Compensation Committee focused on Dr. Smith's key contributions to our successful announcement of PROMISE 1 clinical data and his key role in the development of eptinezumab. In January 2017, the Compensation Committee approved a merit increase of 4.0% to Dr. Smith's 2016 base salary (to US\$414,494 in 2017) in recognition of the individual performance described above and analysis of competitive market salary levels based on survey data. In April 2017, Dr. Smith assumed a leadership position in our wholly owned Irish subsidiary, Alder BioPharmaceuticals Limited. The Compensation Committee in January 2018 also approved a cash bonus of 150,005 under our 2017 executive bonus program in accordance with the level of achievement of the pre-defined corporate performance goals for 2017 (115%) and individual performance (105%) as described above under the heading **Principal Elements of Compensation Annual Incentive Compensation**. Mr. Smith was awarded a grant of stock options to purchase 85,000 shares in January 2017 in accordance with the methods described above under the heading **Principal Elements of Compensation Long-Term Incentive Compensation**. In addition, in December 2017, in recognition of Dr. Smith's continuing contributions to the development of our eptinezumab program, Dr. Smith was awarded a grant of stock options to purchase 50,000 shares.

**Tax and Accounting Considerations**

Prior to December 22, 2017, when the Tax Cuts and Jobs Act of 2017 ( **TCJA** ) was signed into law, Section 162(m) of the Internal Revenue Code of 1986, as amended (the **IRC** ), limited the corporate deduction of publicly traded entities for federal income tax purposes to not more than \$1 million of compensation paid to certain executive officers in a calendar year. Compensation above \$1 million could be deducted if it was performance-based compensation. Under the TCJA, the performance-based exception has been repealed and the \$1 million deduction limit now applies to anyone serving as the chief executive officer or the chief financial officer at any time during the taxable year, and the top three other highest compensated executive officers serving at fiscal year-end. The new rules generally apply to taxable years beginning after December 31, 2017. The TCJA also provides for transitional guidance that will allow certain payments made under written and binding agreements entered into prior to November 2, 2017 to be treated as if they were made under the provisions of Section 162(m) that were in effect prior to enactment of the TJCA.

Prior to the TCJA, the Compensation Committee had not adopted a policy requiring all executive compensation to be deductible, in order to maintain flexibility in compensating our executive officers in a manner designed to promote

our objectives. Going forward, while the Compensation Committee intends to evaluate the effects of the revised compensation limits of Section 162(m) on any compensation it proposes to grant, the Compensation

## **Table of Contents**

Committee intends to continue to provide future compensation in a manner consistent with our best interests and those of our stockholders, including compensation that is potentially not deductible.

We follow the applicable accounting rules for our stock-based compensation awards. In accordance with generally accepted accounting principles, stock-based compensation cost is measured at the grant date, or with respect to performance-based awards, the service inception date, based on the estimated fair value of the awards using a variety of assumptions. This calculation is performed for accounting purposes and, as applicable, reported in the compensation tables, even though recipients may never realize any value from their awards. We expect to record this expense on an ongoing basis over the requisite employee service period. Accounting rules also require us to record cash compensation as an expense at the time the obligation is incurred.

## **Compensation Recovery Policy**

We do not have a policy to attempt to recover cash bonus payments paid to our executive officers if the performance objectives that led to the determination of such payments were to be restated, or found not to have been met to the extent the Compensation Committee originally believed. However, as a public company subject to the provisions of Section 304 of the Sarbanes-Oxley Act of 2002, if we are required as a result of misconduct to restate our financial results due to our material noncompliance with any financial reporting requirements under the federal securities laws, our Chief Executive Officer and principal financial officer may be legally required to reimburse us for any bonus or other incentive-based or equity-based compensation they receive. In addition, we will comply with the requirements of the Dodd-Frank Act and will adopt a compensation recovery policy once the SEC adopts final regulations on the subject.

## **Compensation and Risk**

We believe that risks arising from our compensation policies and practices for our employees are not reasonably likely to have a material adverse effect on our business. In addition, the Compensation Committee believes that the mix and design of the elements of executive compensation do not encourage our employees to assume excessive risks.

## **Summary**

The Compensation Committee believes that our compensation philosophy and programs are designed to foster a performance-oriented culture that aligns employees' interests with those of our stockholders. The Compensation Committee believes that the compensation of our executives is both appropriate and responsive to the goal of improving stockholder value.

## **REPORT OF THE COMPENSATION COMMITTEE<sup>(1)</sup>**

The Compensation Committee of the Board of Directors has reviewed and discussed the Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K with management and, based on such review and discussions, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in this proxy statement.

## **COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS**

Dr. Clay Siegall (Chair)

Mr. Paul Carter

Dr. Deepika Pakianathan

Ms. Wendy Yarno

- (1) The material in this report is not soliciting material, is not deemed filed with the SEC and is not to be incorporated by reference in any filing of the Company under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.

**Table of Contents****COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION**

During 2017, the Compensation Committee consisted of Clay Siegall (chairman), Paul Carter, Deepika R. Pakianathan and Wendy Yarno, none of whom is a current or former officer or employee of Alder.

No member of the Compensation Committee during 2017 or executive officer of Alder has or had a relationship that would constitute an interlocking relationship with executive officers or directors of another entity.

**SUMMARY COMPENSATION TABLE**

The following table sets forth all of the compensation awarded to, earned by or paid to our named executive officers during the years ended December 31, 2017, 2016 and 2015.

Name and Principal Position	Year	Salary	Non-Equity Incentive			Total
			Plan Compensation	Option Awards <sup>(1)</sup>	All Other Compensation	
Randall C. Schatzman, Ph.D.	2017	\$ 560,750	\$ 354,674 <sup>(2)</sup>	\$ 3,261,496	\$ 40,269 <sup>(3)</sup>	\$ 4,217,189
<i>Former President, Chief Executive Officer and Director</i>	2016	525,000	274,313	3,203,126	34,311	4,036,750
	2015	470,000	270,250	2,048,310	32,042	2,820,602
Larry K. Benedict	2017	343,804	129,356 <sup>(2)</sup>	592,999	14,344 <sup>(4)</sup>	1,080,503
<i>Executive Vice President and Principal Accounting Officer</i>	2016	278,634	99,735	1,059,920	13,899	1,452,188
	2015	257,659	86,960	472,687	11,669	828,975
John A. Latham, Ph.D.	2017	441,974	198,888 <sup>(2)</sup>	1,592,184	29,989 <sup>(5)</sup>	2,263,035
<i>Chief Scientific Officer</i>	2016	405,745	170,413	1,354,388	27,811	1,958,357
	2015	392,024	176,411	945,374	25,666	1,539,475
Elisabeth A. Sandoval, M.B.A.,	2017	385,168	230,288 <sup>(2)</sup>	1,844,652	79,037 <sup>(6)</sup>	2,539,145
<i>Chief Commercial Officer and Executive Vice President of Corporate Strategy</i>	2016	129,590	47,341	4,047,754	45,733	4,270,418
Jeffrey T.L. Smith, M.D.	2017 <sup>(7)</sup>	442,665	172,615 <sup>(2)</sup>	1,318,422	126,481 <sup>(8)</sup>	2,060,183
<i>Managing Director of Alder BioPharmaceuticals Limited</i>	2016	398,552	149,955	1,354,388	38,588	1,941,483
	2015	383,223	157,601	787,812	23,642	1,352,278

(1) The amounts in this column reflect the aggregate grant date fair value of each option award granted during the year, computed in accordance with FASB ASC Topic 718. The valuation assumptions used in determining such amounts for 2017 are described in Note 13 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017.

(2) Amounts reported in the non-equity incentive compensation plan column represent bonuses paid under our bonus program. For more information about our executive officer bonus program, see Compensation Discussion and

Analysis Principal Elements of Compensation and Compensation Discussion and Analysis 2017 Compensation Decisions.

- (3) Includes: (a) the value of company paid premiums of \$26,452 for term-life, long-term care and disability insurance, (b) \$13,500 of safe-harbor matching contributions defined in our 401(k) plan and (c) the value of a company gift.
- (4) Includes: (a) \$13,500 of safe-harbor matching contributions defined in our 401(k) plan and (b) the value of a company gift and gym reimbursement amounts.
- (5) Includes: (a) the value of company paid premiums of \$15,722 for term-life, long-term care and disability insurance, (b) \$13,500 of safe-harbor matching contributions defined in our 401(k) plan and (c) gym reimbursement amounts.
- (6) Includes: (a) \$12,004 of safe-harbor matching contributions defined in our 401(k) plan, (b) \$ 66,717 in paid or reimbursed relocation expenses pursuant to her offer letter, including tax gross-ups and (c) the value of a company gift.
- (7) Commencing in March 2017, Dr. Smith was employed and compensated by our wholly owned Irish subsidiary, Alder BioPharmaceuticals Limited. The dollar amounts shown in this table for 2017, except the

**Table of Contents**

amounts in the column titled Option Awards, reflect the US\$ equivalent of the amounts paid to Dr. Smith in Euros. The amounts were converted to U.S. dollars from Euros using the average of the monthly average exchange rates for the nine months ended December 31, 2017. Applying this formula to the nine months ended December 31, 2017, 1.00 was equal to US\$1.151.

- (8) Includes: (a) the value of company paid premiums of \$52,421 for term-life, long-term care and disability insurance, (b) \$16,813 of contributions to Irish pension plan, (c) \$17,955 of payment for vacation accrual, (d) \$39,143 in paid or reimbursed relocation expenses, including tax gross-ups and (e) gym reimbursement amounts.

**GRANTS OF PLAN-BASED AWARDS FOR 2017**

The following table provides information relating to grants of plan-based incentive awards to each of our named executive officers in 2017.

Name	Grant Date	Estimated Future Payouts Under Non-Equity Incentive Plan Awards (Target) <sup>(1)</sup>	All Other Option Awards: Number of Securities Underlying Options	Exercise or Base Price of Option Awards	Grant Date Fair Value of Option Awards <sup>(2)</sup>
Randall C. Schatzman, Ph.D.	N/A 1/27/2017	\$ 308,413	275,000	\$ 20.40	\$ 3,261,496
Larry K. Benedict	N/A 1/27/2017	120,331	50,000	20.40	592,999
John A. Latham, Ph.D.	N/A 1/27/2017 12/14/2017	176,790	95,000 75,000	20.40 10.70	1,126,699 465,485
Elisabeth A. Sandoval, M.B.A.	N/A 1/27/2017 12/20/2017	154,067	75,000 150,000	20.40 10.95	889,499 955,153
Jeffrey T.L. Smith, M.D.	N/A 1/27/2017 12/14/2017	145,073	85,000 50,000	20.40 10.70	1,008,099 310,323

- (1) Represents the target amount of each executive's cash payments under our non-equity incentive compensation plan as established by the Compensation Committee and described in Compensation Discussion and Analysis above. Actual payments made for 2017 are provided in the Summary Compensation Table.
- (2) The amounts in this column reflect the aggregate grant date fair value of each option award granted during the year, computed in accordance with FASB ASC Topic 718. The valuation assumptions used in determining such amounts are described in Note 13 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017.





**Table of Contents****OUTSTANDING EQUITY AWARDS AT DECEMBER 31, 2017**

The following table provides information regarding outstanding equity awards held by each of our named executive officers as of December 31, 2017.

Name	Vesting Commencement Date	Number of Securities Underlying Unexercised Options <sup>(1)</sup>		Option Exercise Price	Option Expiration Date
		Exercisable	Unexercisable		
Randall C. Schatzman, Ph.D.	3/24/2008	78,181		1.65	7/22/2018
	2/24/2009	81,817		0.99	4/20/2019
	2/26/2010	45,453		4.46	2/25/2020
	1/1/2011	45,454		3.96	5/9/2021
	6/13/2012	163,636		3.47	6/12/2022
	1/1/2014	25,814	549 <sup>(2)</sup>	6.77	2/10/2024
	5/7/2014	81,440	9,469 <sup>(2)</sup>	10.00	5/6/2024
	7/8/2014	68,334	11,666 <sup>(2)</sup>	16.90	7/7/2024
	1/1/2015	94,792	35,208 <sup>(2)</sup>	28.23	1/25/2025
	1/1/2016	113,323	123,177 <sup>(2)</sup>	24.18	1/28/2026
	1/1/2017		275,000 <sup>(2)</sup>	20.40	1/26/2027
Larry K. Benedict	6/13/2012	7,444		3.47	6/12/2022
	1/1/2013	9,090		3.47	1/29/2023
	1/1/2014	6,231	132 <sup>(2)</sup>	6.77	2/10/2024
	5/7/2014	4,072	473 <sup>(2)</sup>	10.00	5/6/2024
	7/8/2014	12,813	2,187 <sup>(2)</sup>	16.90	7/7/2024
	1/1/2015	21,875	8,125 <sup>(2)</sup>	28.23	1/25/2025
	1/1/2016	19,167	20,833 <sup>(2)</sup>	24.18	1/28/2026
	10/6/2016	8,750	21,250 <sup>(2)</sup>	30.20	10/5/2026
1/1/2017		50,000 <sup>(2)</sup>	20.40	1/26/2027	
John A. Latham, Ph.D.	2/26/2010	22,727		4.46	2/25/2020
	6/13/2012	95,454		3.47	6/12/2022
	1/1/2014	13,351	284 <sup>(2)</sup>	6.77	2/10/2024
	5/7/2014	16,288	1,893 <sup>(2)</sup>	10.00	5/6/2024
	7/8/2014	34,167	5,833 <sup>(2)</sup>	16.90	7/7/2024
	1/1/2015	43,750	16,250 <sup>(2)</sup>	28.23	1/25/2025
	1/1/2016	47,917	52,083 <sup>(2)</sup>	24.18	1/28/2026
	1/1/2017		95,000 <sup>(2)</sup>	20.40	1/26/2027
	12/14/2017		75,000 <sup>(2)</sup>	10.70	12/13/2027
Elisabeth A. Sandoval, M.B.A.	8/30/2016	75,000	150,000 <sup>(2)</sup>	31.47	10/4/2026
	1/1/2017		75,000 <sup>(2)</sup>	20.40	1/26/2027
	1/1/2018		150,000 <sup>(2)</sup>	10.95	12/19/2027
Jeffrey T.L. Smith, M.D.	3/24/2008	21,363		1.65	7/22/2018
	2/24/2009	40,324		0.99	4/20/2019
	2/26/2010	22,727		4.46	2/25/2020
	6/13/2012	27,272		3.47	6/12/2022

12/12/2012	31,818		3.47	12/11/2022
1/1/2014	13,352	284 <sup>(2)</sup>	6.77	2/10/2024
5/7/2014	12,216	1,420 <sup>(2)</sup>	10.00	5/6/2024
7/8/2014	29,896	5,104 <sup>(2)</sup>	16.90	7/7/2024
1/1/2015	36,459	13,541 <sup>(2)</sup>	28.23	1/25/2025
1/1/2016	47,917	52,083 <sup>(2)</sup>	24.18	1/28/2026
1/1/2017		85,000 <sup>(2)</sup>	20.40	1/26/2027
12/14/2017		50,000 <sup>(2)</sup>	10.70	12/13/2027

- (1) Pursuant to the Severance Plan, the vesting of such named executive officer's option awards will accelerate under certain circumstances as described under Employment and Change in Control Severance Benefits Agreements.
- (2) The unvested shares are scheduled to vest over a four-year period as follows: 25% of the shares underlying the options vest on the one-year anniversary of the vesting commencement date and thereafter 1/48th of the shares vest each month, subject to continued service with us through each relevant vesting date.

**Table of Contents****OPTION EXERCISES IN 2017**

The following table presents, for each of our named executive officers, the number of shares of our common stock acquired upon the exercise of stock options and the aggregate value realized upon the exercise of stock options.

<b>Name</b>	<b>Option Awards</b>	
	<b>Number of Shares Acquired on Exercise</b>	<b>Value Realized on Exercise <sup>(1)</sup></b>
Randall C. Schatzman, Ph.D.	30,000	\$ 701,257
Larry K. Benedict		
John A. Latham, Ph.D.		
Elisabeth A. Sandoval, M.B.A.		
Jeffrey T.L. Smith, M.D.	585	11,121

- (1) The aggregate value realized upon the exercise of an option represents the difference between the aggregate market price of the shares of our common stock on the date of exercise and the aggregate exercise price of the option.

**Employment Agreements***Offer Letters*

We have entered into offer of employment letters with each of the named executive officers in connection with his employment with us. With the oversight and approval of our Board of Directors, each of these employment agreements was negotiated on our behalf by our former Chief Executive Officer, Dr. Randall Schatzman, with the exception of his own employment agreement. These agreements provided for at will employment and set forth the terms and conditions of employment of each named executive officer, including base salary, standard employee benefit plan participation, and the acceleration of the vesting of restricted stock and stock options held by such named executive officers upon the occurrence of certain conditions. These employment agreements were each subject to execution of our standard confidential information and invention assignment agreement.

*Severance Plan*

We adopted the Severance Plan, which became effective in May 2014. The terms of the Severance Plan are summarized above under Post-Termination Protection.

**CEO PAY RATIO**

Under SEC regulations, we are required to calculate and disclose the total annual compensation paid to our median employee, as well as the ratio of the total compensation paid to the median employee as compared to the total compensation paid to our CEO ( *CEO Pay Ratio* ). Set forth below is a description of the methodology, including material assumptions, adjustments and estimates, we used to identify the median employee for purposes of calculating the CEO Pay Ratio:

We identified the median employee using our employee population as of December 31, 2017. For this purpose, we identified all company employees on payroll and all individuals who would receive an IRS Form 1099 from the Company and who did not meet the following exclusion criteria: (i) receipt of annual payments from the Company that totaled less than twenty thousand dollars (\$20,000.00); (ii) employment by another entity, such as employment as faculty of a university; (iii) 1099 recipient constituted a generally recognizable, bona fide service provider such as a law firm or accounting firm; and (iv) 1099 recipient employed more than two or more employees and has other bona fide clients.

In determining compensation for purposes of the median calculation, we used each employee's annual base pay, annual bonus and regular annual equity awards (at grant date fair value). For individuals receiving 1099s and not excluded based on the criteria above, the amount of compensation reflected in the individual's Form 1099 was the annual compensation number utilized.

**Table of Contents**

We annualized the base salary earned in 2017 by permanent employees (full-time and part-time) hired after January 1, 2017.

Using this approach, we selected the median of our employee population. Once the median employee was identified, we then calculated annual total compensation for this employee in accordance with the requirements of the Summary Compensation Table.

For 2017, the median of the annual total compensation of our employees (other than our CEO) was \$163,432 and the annual total compensation of our CEO was \$4,217,189. The ratio of the annual total compensation of our CEO to the median of the annual total compensation of all employees other than the CEO was 25.8.

The pay ratio above represents the Company's reasonable estimate calculated in a manner consistent with the rule and applicable guidance. The rule and guidance provide significant flexibility in how companies identify the median employee, and each company may use a different methodology and make different assumptions particular to that company. As a result, as the SEC explained when it adopted the rule, in considering the pay-ratio disclosure, stockholders should keep in mind that the rule was not designed to facilitate comparisons of pay ratios among different companies, even companies within the same industry, but rather to allow stockholders to better understand and assess each particular company's compensation practices and pay-ratio disclosures.

Neither the Compensation Committee nor our management used our CEO Pay Ratio measure in making compensation decisions.

**Table of Contents****POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE IN CONTROL**

The following table provides information concerning the estimated payments and benefits that each named executive officer would be entitled under the Severance Plan. Payments and benefits are estimated assuming that the triggering event took place on December 31, 2017. There can be no assurance that a triggering event would produce the same or similar results as those estimated below if such event occurs on any other date or at any other price, or if any other assumption used to estimate potential payments and benefits is not correct. Due to the number of factors that affect the nature and amount of any potential payments or benefits, any actual payments and benefits may be different.

<b>Name and Principal Position</b>	<b>Non-Change in Control (\$)</b>	<b>Involuntary Termination Upon Change in Control or within 12 months Upon Change in Control (\$)</b>
<b>Randall C. Schatzman, Ph.D.</b>		
<i>Former President, Chief Executive Officer and Director</i>		
Base salary	841,125	841,125
Bonus award	462,619	462,619
Vacation payout	64,800	64,800
Health benefit continuation	39,421	39,421
Stock award acceleration		16,302
	<b>1,407,965</b>	<b>1,424,267</b>
<b>Larry K. Benedict</b>		
<i>Executive Vice President and Principal Accounting Officer</i>		
Base salary	343,804	343,804
Bonus award	120,331	120,331
Vacation payout	3,383	3,383
Health benefit continuation	26,280	26,280
Stock award acceleration		1,304
	<b>493,798</b>	<b>495,102</b>
<b>John A. Latham, Ph.D.</b>		
<i>Chief Scientific Officer</i>		
Base salary	441,974	441,974
Bonus award	176,790	176,790
Vacation payout	42,682	42,682
Health benefit continuation	17,029	17,029
Stock award acceleration		60,325
	<b>678,475</b>	<b>738,800</b>

**Elisabeth A. Sandoval**

*Chief Commercial Officer and Executive Vice President  
of Corporate Strategy*

Base salary	256,779	256,779
Bonus award	102,711	102,711
Vacation payout	37,000	37,000
Health benefit continuation	26,280	26,280
Stock award acceleration		75,000
	<b>422,770</b>	<b>497,770</b>



**Table of Contents**

<b>Name and Principal Position</b>	<b>Non-Change in Control (\$)</b>	<b>Involuntary Termination Upon Change in Control or within 12 months Upon Change in Control (\$)</b>
<b>Jeff T.L. Smith<sup>(4)</sup></b>		
<i>Managing Director of Alder BioPharmaceuticals Limited</i>	467,496	467,496
Bonus award	163,623	163,623
Vacation payout	51,750	51,750
Health benefit continuation	5,360	5,360
Stock award acceleration		40,890
	<b>688,229</b>	<b>729,119</b>

- (1) Represents amounts payable under the terms of the Severance Plan, in the event we involuntarily terminate any participant for any reason other than cause, death or disability, and such termination is not in connection with or within 12 months following a change in control.
- (2) Represents amounts payable under the Severance Plan due to the acceleration of vesting in connection with a change in control in the event (a) the outstanding and unvested stock options are not assumed or substituted with similarly equivalent options in such change in control or (b) we involuntarily terminate any participant for any reason other than cause, death or disability, or the participant resigns for Good Reason (as defined in the Severance Plan), and such termination or resignation occurs in connection with or within 12 months following a change in control. In addition, Dr. Schatzman will be entitled to such acceleration of vesting in the event he remains employed by Alder or its successor on the one-year anniversary of the change in control.
- (3) The value of stock award vesting acceleration is based on the closing stock price of \$11.45 per share for our common stock as reported on the Nasdaq Global Market on December 29, 2017.
- (4) Commencing in March 2017, Dr. Smith was employed and compensated by our wholly owned Irish subsidiary, Alder BioPharmaceuticals Limited. The dollar amounts shown in this table, except the amounts in the row titled Stock award acceleration, reflect the US\$ equivalent of the amounts payable to Dr. Smith in Euros. The amounts were converted to U.S. dollars from Euros using exchange rate at December 31, 2017, where 1.00 was equal to US\$1.199861.

**Table of Contents****EQUITY COMPENSATION PLAN INFORMATION**

The following table summarizes information about our equity compensation plans as of December 31, 2017. All outstanding awards relate to our common stock.

<b>Plan Category</b>	<b>(a) Number of Securities to be Issued Upon Exercise of Outstanding Options</b>	<b>(b) Weighted-Average Exercise Price of Outstanding Options</b>	<b>(c) Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a))</b>
Equity compensation plans approved by security holders:			
2005 Stock Option Plan	1,025,263	\$ 3.47	
2014 Equity Incentive Plan <sup>(1)</sup>	6,261,571	23.18	1,504,604
2014 Employee Stock Purchase Plan <sup>(1)</sup>		N/A	1,183,862
Equity compensation plans not approved by security holders:		N/A	
<b>Total</b>	<b>7,286,834</b>	<b>N/A</b>	<b>2,688,466</b>

- (1) Our 2014 Equity Incentive Plan includes provisions providing for an annual increase in the number of securities available for future issuance on the first day of each calendar year, equal to the lesser of: (a) 4% of the outstanding shares of common stock as of the last day of the immediately preceding calendar year; and (b) such other amount as the Board of Directors may determine. Our 2014 Employee Stock Purchase Plan includes provisions providing for an annual increase in the number of securities available for future issuance on the first day of each calendar year, equal to the lesser of: (a) 1% of the outstanding shares of common stock on the first day of such calendar year; and (b) 750,000 shares of common stock; provided that the Board of Directors, or a committee appointed by the Board of Directors, may determine that there shall be no increase or a lesser increase than the foregoing for any given calendar year.

**Table of Contents****TRANSACTIONS WITH RELATED PERSONS**

Other than compensation arrangements for our directors and named executive officers, which are described elsewhere in this proxy statement, below we describe transactions since January 1, 2017 to which we were a party or will be a party, in which:

the amounts involved exceeded or will exceed \$120,000; and

any of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of, or person sharing the household with, the foregoing persons, had or will have a direct or indirect material interest.

**PREFERRED STOCK PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENT**

On January 7, 2018, we entered into a Preferred Stock Purchase Agreement (the *Purchase Agreement*) with certain institutional and other accredited investors affiliated with or managed by Redmile Group, LLC (collectively, the *Buyers*). Pursuant to the Purchase Agreement, on January 12, 2018, we sold to the Buyers in a private placement 725,268 shares of Class A-1 Convertible Preferred Stock (the *Preferred Shares*) at \$137.88 per share (the *Initial Purchase Price*) for net proceeds to the Company of approximately \$97.7 million, after deducting fees and applicable expenses. In addition, pursuant to the Purchase Agreement, in the event a deemed liquidation event occurs within 24 months of the date of the Purchase Agreement, we will issue the Buyers (or their designees or assignees) a warrant to purchase an aggregate of 75,000 shares of convertible preferred stock at a purchase price per share equal to the Initial Purchase Price (share number and exercise price each subject to adjustment for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction) (the *Warrant*). In connection with the Purchase Agreement, we entered into a registration rights agreement with the Buyers. Under the registration rights agreement, we filed a prospectus supplement under our current registration statement on Form S-3 (SEC File No. 333-216199), and are required to file, if needed, one or more additional registration statements, as permissible and necessary, for the resale of the shares of our common stock issued or issuable upon conversion of the Preferred Shares and the shares of convertible preferred stock issuable upon exercise of the Warrant. The Purchase Agreement and our right to sell an additional \$150 million of convertible preferred stock terminated on February 1, 2018 upon the closing of our underwritten public offering (the *Notes Offering*) of 2.5% convertible senior notes due 2025 (the *2025 Notes*) and no additional shares will be issued under the Purchase Agreement, except in the event that the Warrant is issued and/or exercised. Private investment vehicles and separately managed accounts for which Redmile Group, LLC is the investment manager/adviser purchased \$25.0 million aggregate principal amount of the 2025 Notes in the Notes Offering. In April 2018, upon the recommendation of our Nominating and Corporate Governance Committee, the Board appointed Jeremy Green, the managing member of Redmile Group, LLC, to serve as a Class III director.

**INVESTOR RIGHTS AGREEMENT**

We are party to an investor rights agreement that provides holders of our preferred stock, including certain holders of more than 5% of our capital stock and entities affiliated with certain of our directors, with certain registration rights, including the right to demand that we file a registration statement or request that their shares be covered by a registration statement that we are otherwise filing.

The registration of shares of our common stock pursuant to the exercise of certain registration rights would enable the holders to sell these shares without restriction under the Securities Act, when the applicable registration statement is

declared effective. We will pay the registration expenses, other than underwriting discounts and commissions, of the shares registered pursuant to certain demand, piggyback and Form S-3 registrations.

**Table of Contents**

**INDEMNIFICATION AGREEMENTS**

Our amended and restated certificate of incorporation provides that we may indemnify our directors, officers, employees and other agents to the maximum extent permitted by the Delaware General Corporation Law, and our amended and restated bylaws provide that we will indemnify our directors and officers and may indemnify our other employees and other agents to the maximum extent permitted by the Delaware General Corporation Law. In addition, we have entered and expect to continue to enter into agreements to indemnify our directors and executive officers.

**POLICY ON FUTURE RELATED PARTY TRANSACTIONS**

Our Board of Directors has adopted a policy that our executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of any class of our capital stock and any members of the immediate family of any of the foregoing persons are not permitted to enter into a related person transaction with us without the prior consent of our Audit Committee. Any request for us to enter into a transaction with an executive officer, director, nominee for election as a director, beneficial owner of more than 5% of any class of our common stock or any member of the immediate family of any of the foregoing persons in which the amount involved exceeds \$120,000 and such person would have a direct or indirect interest must first be presented to our Audit Committee for review, consideration and approval. In approving or rejecting any such proposal, our Audit Committee is to consider the material facts of the transaction, including, but not limited to, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related person's interest in the transaction.

**Table of Contents**

**HOUSEHOLDING OF PROXY MATERIALS**

The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for Annual Meeting materials with respect to two or more stockholders sharing the same address by delivering a single set of Annual Meeting materials addressed to those stockholders. This process, which is commonly referred to as householding, potentially means extra convenience for stockholders and cost savings for companies.

This year, a number of brokers with account holders who are Alder stockholders will be householding the Company's proxy materials. A single set of Annual Meeting materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be householding communications to your address, householding will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in householding and would prefer to receive a separate set of Annual Meeting materials, please notify your broker or Alder. Direct your written request to Corporate Secretary, Alder BioPharmaceuticals, Inc. 11804 North Creek Parkway South, Bothell, WA 98011 or contact our Corporate Secretary at (425) 205-2900. Stockholders who currently receive multiple copies of the Annual Meeting materials at their addresses and would like to request householding of their communications should contact their brokers.

**Table of Contents**

**OTHER MATTERS**

The Board of Directors knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the meeting, it is the intention of the persons named in the accompanying proxy to vote on such matters in accordance with their best judgment.

By Order of the Board of Directors

Mark Litton

Chief Business Officer, Treasurer and Corporate Secretary

April 30, 2018

**A copy of the Company's Annual Report to the Securities and Exchange Commission on Form 10-K for the fiscal year ended December 31, 2017 is available without charge upon written request to: Corporate Secretary, Alder BioPharmaceuticals, Inc. 11804 North Creek Parkway South, Bothell, WA 98011.**

**Table of Contents**



**Table of Contents**